预约演示
更新于：2026-04-08
Posaconazole
泊沙康唑
更新于：2026-04-08
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C37H42F2N8O4 |
InChIKeyRAGOYPUPXAKGKH-XAKZXMRKSA-N |
CAS号171228-49-2 |
关联
176
项与 泊沙康唑 相关的临床试验NCT07261150
Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)
The purpose of the study is threefold:
1. Assess the safety and efficacy of a single high-dose intravenous (LAmB 10mg/kg) compared to the SOC daily dosing (3mg/kg) of the same medication for induction therapy in moderate to severe histoplasmosis.
2. Assess the safety and efficacy of oral posaconazole 300mg delayed-release tablets three times daily for two days then once daily for consolidation therapy compared to SOC oral itraconazole 200 mg capsules three times daily for three days then twice daily in moderate to severe histoplasmosis
3. Assess the safety and efficacy of 6 months of consolidation therapy compared to the SOC 12 months of consolidation therapy in persons with HIV on appropriate antiretroviral therapy.
1. Assess the safety and efficacy of a single high-dose intravenous (LAmB 10mg/kg) compared to the SOC daily dosing (3mg/kg) of the same medication for induction therapy in moderate to severe histoplasmosis.
2. Assess the safety and efficacy of oral posaconazole 300mg delayed-release tablets three times daily for two days then once daily for consolidation therapy compared to SOC oral itraconazole 200 mg capsules three times daily for three days then twice daily in moderate to severe histoplasmosis
3. Assess the safety and efficacy of 6 months of consolidation therapy compared to the SOC 12 months of consolidation therapy in persons with HIV on appropriate antiretroviral therapy.
开始日期2026-05-01 |
申办/合作机构 |
NCT07155226
A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with homeobox (HOX) overexpression.
开始日期2026-01-09 |
申办/合作机构 |
CTR20253591
泊沙康唑口服混悬液在空腹条件下的人体生物等效性试验
考察健康受试者在空腹状态下，单次口服由华益泰康药业股份有限公司提供的泊沙康唑口服混悬液（受试制剂T，规格：40mg/mL）与单次口服由Merck Sharp And Dohme B.V.持证的泊沙康唑口服混悬液（参比制剂R，商品名：Noxafil®，规格：40mg/mL）的药动学特征，评价两制剂间的生物等效性和安全性，为该受试制剂注册申请提供依据
开始日期2025-09-16 |
申办/合作机构 |
100 项与 泊沙康唑 相关的临床结果
登录后查看更多信息
100 项与 泊沙康唑 相关的转化医学
登录后查看更多信息
100 项与 泊沙康唑 相关的专利（医药）
登录后查看更多信息
3,564
项与 泊沙康唑 相关的文献（医药）2026-05-01·PSYCHIATRY RESEARCH
Personalized approach to cognitive remediation for people with schizophrenia and autism
Article
作者: Péchaud, Louise ; Attali, David ; Gaillard, Raphaël ; Launay, Corinne ; Todd, Aurélia ; Mendy, Mauricette ; Amado, Isabelle ; Brenugat, Lindsay ; Moualla, Mona ; Prost, Zelda ; Rigaut, Bérangère ; Maitre, Alienor ; Morvan, Yannick ; Danset, Charlotte ; Jabeur, Myriam ; Vinckier, Fabien
OBJECTIVE:
People with schizophrenia (PSCZ) and autism spectrum disorders (PASD) suffer from cognitive impairment. Cognitive remediation (CR) interventions aim to enhance cognition, but the approach is often not customized to meet the participants' needs. The Neuropsychological Educational Approach to Remediation - Medalia 2002 (NEAR)- enhances intrinsic motivation. Here participants are choosing cognitive goals according to their cognitive profile, and their training is adjusted accordingly. The aims of this study were 1. To demonstrate patient progress with NEAR for schizophrenia and autism 2. To see if adapted cognitive objectives before the NEAR program, with selected cognitive functions, improved specific clinical, functional and neuropsychological outcomes.
METHODS:
Fifty-one PSCZ and 17 PASD performed 30-biweekly-group-sessions with selected goals and pre/post program assessments for symptomatology, autonomy, self-esteem, quality-of-life, apathy, attention, working and verbal memory, and inhibition.
RESULTS:
PSCZ improved overall, but PASD only improved for self-esteem, attention, and long-term recall. Within the Total Group (PTG), comparing Trained (T) and Non-trained (NT) showed increased performance: for "speed", in executive and verbal learning; for "attention", in attention, verbal learning and executive functions; for "working memory", in Digit span backward, verbal learning and executive functions; for "verbal learning", in verbal recall, attention and executive functions; for "executive", in attention, verbal learning, executive performances.
CONCLUSIONS AND IMPLICATION FOR PRACTICE:
Participants with schizophrenia progressed after NEAR in clinical, functional and cognitive aspects, as well as self-esteem, attention and verbal memory dimensions in autism. The good matches between goals and observed change can optimize adherence and satisfaction to this therapy.
2026-04-01·JOURNAL OF PHARMACY TECHNOLOGY
Treatment of Histoplasmosis With Posaconazole in the Setting of a Severe Itraconazole Hypersensitivity Reaction: A Case Report
Article
作者: Durham, Spencer H. ; Johannemann, Kinsey M. ; Allos, Samir ; Belk, Madeline ; Roberts, Megan Z. ; Edwards, Jonathan D.
Objective:
Itraconazole is recommended as the first-line oral treatment for pulmonary histoplasmosis. There is a paucity of data describing hypersensitivity reactions to itraconazole and lack of clarity on triazole antifungal cross-reactivity.
Case:
Approximately 9 hours after an initial dose of itraconazole 200 mg for treatment of chronic cavitary pulmonary histoplasmosis, a 72-year immunocompetent patient developed anaphylactic symptoms that abated with intervention. To resume histoplasmosis treatment in the setting of limited treatment options following nephrotoxicity that occurred while receiving amphotericin B, a single posaconazole 100 mg tablet was given and well tolerated by the patient. Subsequently a treatment course of posaconazole 300 mg began with confirmation of therapeutic drug levels prior to hospital discharge. Imaging after 2 months of posaconazole showed improvement in cavitation size.
Conclusion:
Posaconazole was a safe and effective alternative to itraconazole for chronic cavitary pulmonary histoplasmosis in this case. Further evaluation of mechanisms and management of triazole hypersensitivity reactions are warranted.
2026-04-01·MYCOPATHOLOGIA
Antifungal Susceptibility and Multilocus Sequence Typing of Pichia kudriavzevii (Candida krusei) from a Tertiary Hospital in Shanghai
Article
作者: Li, Li ; Chen, Guo ; Wan, Jieyi ; Han, Demin ; Huang, Yixin ; Zhu, Junhao ; Zhu, Min
The incidence of infections by non-albicans Candida species, including Pichia kudriavzevii (formerly Candida krusei) has been increasing. P. kudriavzevii exhibits intrinsic resistance to fluconazole (FLU) and rapidly develops acquired resistance to other antifungals. However, large-scale epidemiological, antifungal susceptibility, and genotyping data from mainland China remain limited. We analyzed the clinical and laboratory data of 203 P. kudriavzevii isolates spanning from 2017 to 2023. In vitro antifungal susceptibility testing was performed by the Sensititre YeastOne microdilution method. The genotyping of P. kudriavzevii isolates was analysed by multilocus sequence typing (MLST). The results showed that P. kudriavzevii were predominantly isolated from sputum (132, 65.02%) and urine (21, 10.34%). Patients with P. kudriavzevii isolation were mainly from the Infectious Diseases Department (50, 24.63%), Intensive Care Unit (lCU) (45, 22.17%) and General Surgery (32, 15.76%), and the pathogen was highly prevalent in individuals over 60 years old. All isolates exhibited intrinsic resistance to FLU. The resistance rate to voriconazole (VOR) was 9.4% (19/203), showing an increasing trend. 80 isolates (39.41%) were non-wild-type (NWT) to amphotericin B (AMB) and posaconazole (POS). Excluding FLU, 31 isolates (15.27%) exhibited a resistant or NWT phenotype to at least two distinct antifungal agent classes, and the MLST analysis of them revealed 16 distinct diploid sequence types (DST) profiles. Among these, ST195 (7, 22.6%) and ST268 (6, 19.4%) were the predominant genotypes associated with antifungal resistance, and 58.1% of the resistant sequence types exhibited resistance to VOR. Continuous monitoring of antifungal susceptibility and molecular typing is essential. This study provides valuable insights for managing P. kudriavzevii infections and guiding clinical treatment strategies.
427
项与 泊沙康唑 相关的新闻（医药）2026-04-06
·医缘随笔
《英国医学真菌学会严重真菌病诊断最佳实践建议：2025年更新》详细总结
超越指南：处理真菌诊断时我需要了解什么？
危重症患者突破性真菌感染的高危因素、诊断和治疗要点
侵袭性肺真菌病诊断与治疗指南（2025年版）重症监护病房患者抗真菌治疗策略
一、引言（一）侵袭性真菌感染的现状
侵袭性真菌感染（IFIs）是导致重症患者发病和死亡的重要原因。在重症监护病房（ICU）中，侵袭性念珠菌病（IC）、侵袭性肺曲霉病（IPA）和耶氏肺孢子菌肺炎（PjP）是最为常见且具有临床重要性的真菌疾病。这些疾病的诊断往往面临诸多困难，如非特异性的临床和放射学表现、培养结果延迟或阴性以及真菌生物标志物在该人群中的性能不佳等。因此，ICU中的抗真菌治疗策略需要在早期启动治疗与过度治疗及耐药风险之间取得平衡。（二）研究目的与方法
本综述旨在总结针对重症患者中IC、IPA和PjP的当前治疗方法、循证建议以及最新进展，同时探讨药代动力学/药效学（PK/PD）考虑因素、治疗药物监测和新兴抗真菌药物。研究通过在PubMed数据库检索2025年9月1日前发表的英文文章，使用相关关键词的不同组合，重点关注过去5年发表的研究，筛选出涉及重症患者的多中心研究和随机临床试验进行分析。二、侵袭性念珠菌病（IC）（一）流行病学与临床特点1. 发病率与死亡率
IC仍然是ICU面临的主要挑战，与高发病率和死亡率相关。大型多中心EUCANDICU研究报告显示，每1000例ICU入院患者中约有7.07例发病，其中念珠菌血症约占病例的四分之三，腹腔内念珠菌病约占近四分之一，死亡率超过40%，这反映了该人群疾病的严重程度。2. 菌种分布
过去十年，念珠菌菌种分布逐渐从白色念珠菌向非白色念珠菌转变，非白色念珠菌现在占ICU病例的一半以上。然而，这种模式在不同的ICU人群中可能并不一致。其中，耳念珠菌已成为重要的医疗相关病原体，感染率上升，且在ICU中多次暴发，尤其是在COVID - 19疫情期间及之后。其高效传播和不确定的长期定植使得控制变得困难，尤其是在ICU环境中。从临床角度来看，尽管大多数研究未显示耳念珠菌感染患者的30天或90天死亡率高于其他念珠菌菌种，但耳念珠菌与更高的微生物复发风险相关，因此需要密切随访。同样，耐唑类的近平滑念珠菌感染也越来越频繁，发病率上升且有暴发报告，尤其是在COVID - 19疫情之后。（二）治疗方法
1. 预防策略
预防策略在非中性粒细胞减少和非移植ICU人群中并未显示出明确的死亡率益处，因此不常规推荐使用。仅在极少数特定高危情况下，如近期接受腹部手术且并发反复穿孔或吻合口裂开的患者，可考虑使用预防策略。2. 经验性抗真菌治疗
经验性抗真菌治疗是指在存在感染临床怀疑（基于危险因素和相应体征或症状）但缺乏微生物学确认或生物标志物支持的情况下启动抗真菌治疗。随机对照试验显示，与安慰剂相比，经验性抗真菌治疗在提高生存率方面未显示出明确益处。然而，在某些选定病例中，如感染性休克患者或临床状况迅速恶化且有明确危险因素（如多部位念珠菌定植或长期ICU住院）的患者，经验性治疗可能仍是合理选择。3. 诊断驱动的治疗方法
基于真菌生物标志物的诊断驱动方法正逐渐被探索，以优化治疗的启动和停止。血清β - D - 葡聚糖（BDG）是研究最广泛的生物标志物之一，但在ICU中的临床应用因假阳性率高（如腹部手术或静脉注射免疫球蛋白后）以及对某些菌种（如耳念珠菌和近平滑念珠菌）的敏感性降低而受到限制。CANDISEP试验表明，基于BDG启动抗真菌治疗在改善28天死亡率方面并不优于基于培养的策略，但会显著增加抗真菌药物的暴露。而BDG指导的停药策略可能具有一定优势，但现有证据结果不一。4. 靶向抗真菌治疗
一旦感染确诊，靶向抗真菌治疗仍是治疗的基石。目前指南推荐棘白菌素类作为念珠菌血症和其他形式IC的一线治疗药物，因其具有广谱、杀真菌活性和良好的安全性。在病情稳定、血培养清除、菌种敏感且有充分源头控制的无并发症病例中，建议逐步降级为唑类药物（通常为氟康唑）。及时移除感染的血管内导管、引流脓肿和手术处理感染病灶是治疗的重要组成部分，与抗真菌治疗同等重要。此外，新型抗真菌药物如瑞扎芬净（rezafungin）、福沙康唑（fosmanogepix）和艾沙康唑（ibrexafungerp）等正在进入临床开发的后期阶段，可能为未来的侵袭性念珠菌病治疗提供更多选择。（三）药代动力学/药效学（PK/PD）问题与治疗药物监测（TDM）
ICU患者的PK/PD变异性较大，如液体分布改变、低蛋白血症、器官功能障碍、体外治疗（如肾脏替代治疗或体外膜肺氧合）以及多种药物相互作用等都会影响药物暴露和疗效。因此，剂量优化和TDM（尤其是三唑类药物）是确保治疗疗效和避免毒性的合理方法。对于棘白菌素类药物，在特定情况下（如持续肾脏替代治疗期间）的剂量优化仍存在争议，其TDM的作用也在探讨中，可能在某些选定病例中用于评估是否需要增加剂量以避免药物暴露不足。（四）治疗持续时间
侵袭性念珠菌病的抗真菌治疗持续时间因感染部位而异，对于念珠菌血症，目前仍建议在首次血培养阴性后至少继续治疗14天，但也有研究关注缩短抗真菌治疗疗程的可能性，提出了“无并发症念珠菌血症”的定义，但该定义尚未在前瞻性临床研究中得到验证，因此目前仍遵循传统的治疗持续时间建议。三、侵袭性肺曲霉病（IPA）（一）流行病学与临床特点
IPA传统上与中性粒细胞减少和严重免疫抑制相关，但现在在ICU的非中性粒细胞减少重症患者中也越来越常见。全球每年估计有20万 - 100万例病例，占内科ICU入院人数的1% - 5%，在流感和COVID - 19疫情期间发病率进一步上升，死亡率仍然很高，每年约有40万人死亡，其中约一半直接归因于IPA。多种宿主相关因素易使重症患者患IPA，包括严重病毒性肺炎、长期使用皮质类固醇、肝功能衰竭、慢性呼吸系统疾病（如COPD）、未控制的HIV感染、实体瘤和创伤（包括严重烧伤）等。（二）诊断挑战
IPA的临床表现非特异性，经典的放射学表现在ICU患者中并不常见。EORTC/MSGERC标准在免疫功能低下人群中是标准，但在ICU患者中过于严格。一些替代定义如Asp - ICU算法、其生物标志物增强版本（Asp - ICU - BM）和最新的FUNDICU标准已被开发出来以提高诊断准确性，但FUNDICU标准主要用于研究目的，在日常临床实践中的直接应用有限。不过，通过纳入其他宿主因素，如中度或重度急性呼吸窘迫综合征（ARDS）和心脏手术后等情况，更新后的FUNDICU - 临床算法可显著提高诊断性能，敏感性达到97%，特异性达到63%。（三）治疗方法1. 一线和替代抗真菌治疗
目前ICU患者IPA的一线治疗依赖于具有抗霉菌活性的三唑类药物，主要是伏立康唑和艾沙康唑。伏立康唑具有最强的疗效证据，其高口服生物利用度可实现从静脉到口服制剂的早期转换，可能有助于缩短住院时间并减少静脉导管相关并发症。但伏立康唑由于非线性药代动力学、显著的个体间变异性以及不良反应风险（尤其是肝毒性和神经毒性），需要进行TDM。艾沙康唑是一种新型广谱唑类药物，与伏立康唑相比具有非劣效性，且安全性更好，不良反应（如肝毒性、皮肤和视觉不良反应）和药物相互作用更少。泊沙康唑也被研究作为治疗选择，在一项试验中显示与伏立康唑非劣效，但在IPA中的临床应用主要局限于高危人群的预防和补救治疗。脂质体两性霉素B（L - AmB）仍是重要的替代药物，尤其是在唑类耐药、禁忌或不耐受的情况下。棘白菌素类药物通常用于补救治疗或作为难治性疾病的辅助药物。2. 治疗策略
(1)抢先治疗：抢先治疗主要基于半乳甘露聚糖检测阳性或胸部CT显示肺部浸润，但在ICU患者中，由于缺乏支持其常规使用的足够证据，不推荐抢先治疗。
(2)预防治疗：支持ICU患者预防策略的证据有限，除实体器官移植受者外，不推荐常规使用抗霉菌预防治疗。一项前瞻性多中心病例对照研究（POSACOVID）评估了泊沙康唑预防在接受皮质类固醇治疗的机械通气COVID - 19患者中的应用，结果显示不同中心的COVID - 19相关肺曲霉病（CAPA）发病率存在差异，且该研究未评估生存结局，因此无法得出泊沙康唑预防对死亡率影响的结论。
(3)经验性治疗：由于IPA的高死亡率，一旦临床怀疑IPA，应尽快启动经验性抗真菌治疗。目前经验性治疗主要依赖于具有抗霉菌活性的三唑类药物。3. 联合治疗与补救治疗
联合抗真菌治疗作为一线和补救治疗的研究较多，但在非中性粒细胞减少ICU患者中的证据仍然稀缺且主要是观察性研究。现有数据并不支持联合治疗优于单药治疗，但在某些高危或补救治疗环境中可能存在潜在益处。需要针对重症、非血液学人群设计前瞻性研究来明确联合治疗的作用。（四）PK/PD问题与TDM
某些抗真菌药物（如伏立康唑和泊沙康唑）由于其药代动力学特点需要TDM。在ICU患者中，PK/PD与注册试验中纳入的人群存在显著差异，个体间变异性大，因此应考虑对所有抗真菌药物进行TDM。SAFE - ICU研究表明，抗真菌药物的血浆浓度常常未达到推荐目标，这与较差的预后相关。一些研究也显示，ICU患者中艾沙康唑的药代动力学变异性大，亚治疗浓度常见，因此在该人群中考虑TDM是合理的。（五）新型抗真菌药物与未来方向
抗真菌耐药性和难治性感染的出现推动了新型抗真菌药物的开发，一些药物已进入II期或III期临床试验。如奥罗菲姆（olorofim）是一种新型二氢乳清酸脱氢酶抑制剂，对包括唑类或两性霉素B耐药菌株在内的曲霉属具有强大的体外活性；福沙康唑（fosmanogepix）是一种新型Gwt1抑制剂，对酵母菌和霉菌具有广谱活性，包括唑类耐药的烟曲霉。吸入性抗真菌药物（如opelconazole）也在研究中，作为严重或难治性侵袭性肺曲霉病的辅助治疗。免疫治疗方法（如过继转移真菌特异性T细胞）目前仍处于实验阶段，但显示出对宿主导向治疗的兴趣日益增加。四、耶氏肺孢子菌肺炎（PjP）（一）流行病学与临床特点
PjP历史上主要被认为是影响人类免疫缺陷病毒（HIV）感染者的严重机会性感染，但近年来，由于自身免疫性疾病、血液系统恶性肿瘤和实体瘤等疾病广泛使用免疫抑制治疗（包括生物制剂和皮质类固醇），高危人群范围扩大。在一项回顾性机构队列研究中，240例患者的年平均发病率为13±5例，其中41.7%的患者需要ICU住院，36.6%接受机械通气，16.3%接受肾脏替代治疗，4.5%接受ECMO支持，住院总死亡率为25.4%，接受ICU治疗的患者死亡率上升至58%，而非ICU患者死亡率仅为1.6%。HIV感染者死亡率最低（12.8%），实体器官移植受者（38.4%）、风湿性疾病患者（30.0%）和血液系统恶性肿瘤患者（44.7%）死亡率较高。（二）治疗方法1. 一线和替代治疗
复方磺胺甲恶唑（TMP/SMX）是HIV感染者和非HIV免疫功能低下患者PjP的首选治疗药物。对于不能耐受TMP/SMX或有禁忌证的患者，有几种二线治疗选择，如静脉喷他脒、克林霉素联合伯氨喹、阿托伐醌、氨苯砜联合甲氧苄啶等，但这些二线药物都有各自的不良反应和使用注意事项。2. 联合治疗
目前尚无随机对照试验评估联合抗菌策略治疗PjP的疗效和安全性，在ICU中的证据也很有限。但一些回顾性队列和观察性研究探索了联合方案（尤其是包括棘白菌素类药物）的潜在作用，动物模型研究表明TMP/SMX与棘白菌素类药物在促进感染清除方面具有协同作用。一项荟萃分析显示，TMP/SMX联合棘白菌素类药物与TMP/SMX单药治疗相比，死亡率显著降低，但这种死亡率益处主要在HIV感染者中观察到，而非HIV患者中。在重症患者中，一些回顾性研究显示初始联合治疗可能提高临床反应率，但在死亡率方面的改善并不一致。3. 辅助皮质类固醇治疗
对于HIV感染且患有中重度PjP（定义为室内空气动脉血氧分压（PaO2）低于70 mmHg或肺泡 - 动脉氧梯度大于35 mmHg）的成人和青少年，推荐使用辅助皮质类固醇治疗，应在启动抗菌治疗后尽快开始（理想情况下在72小时内），可降低死亡率和机械通气需求。但对于非HIV重症患者，目前关于辅助皮质类固醇治疗的益处尚无明确结论，一项随机对照试验显示，辅助皮质类固醇治疗在降低28天死亡率方面与安慰剂相比无统计学显著差异，但在90天死亡率方面有改善趋势，因此在获得进一步证实性证据之前，可在某些选定病例中考虑使用辅助皮质类固醇治疗。五、结论
侵袭性真菌感染仍然是ICU患者面临的主要挑战，需要及时识别、靶向治疗和优化抗真菌管理。诊断技术的进步、新型抗真菌药物的出现和药代动力学/药效学策略的改进正逐步改善患者预后。然而，个体化管理仍然至关重要，需考虑病原体、宿主因素和药物特性。未来的研究应侧重于整合快速诊断和实时治疗监测，以指导早期、个性化治疗，并减少ICU中不必要的抗真菌药物暴露。下列为文中的附表表1：重症监护病房成人患者侵袭性真菌病（FUNDICU）诊断标准确诊侵袭性肺曲霉病定义
符合以下至少一项即可确诊：
1.通过活检或针吸从正常无菌部位或肺部获取标本，经组织学或细胞病理学检查显示存在曲霉属真菌菌丝侵袭，并经培养或PCR检测确认。
2.通过活检或针吸从与感染性病变相符的无菌部位标本中培养出曲霉属真菌。临床诊断肺曲霉病（IPA）和气管支气管曲霉病（TBA）定义
仅对具备以下至少一项相应体征和症状的患者进行评估（评估前提条件）：
1.经至少3天适当抗生素治疗后仍持续发热（体温≥38.3°C）（必要时需控制细菌感染源）。
2.已使用抗生素且退热至少48小时后再次发热，且无其他明显诱因。
3.胸膜炎性胸痛。
4.胸膜摩擦音。
5.呼吸困难a。
6.咯血。
7.经合适抗生素治疗和呼吸支持后呼吸功能仍恶化。
具备至少一项相应体征或症状的患者，需评估是否存在以下至少一项ICU宿主因素：
1.流感。
2.COVID-19。
3.中/重度慢性阻塞性肺疾病（COPD）。
4.失代偿期肝硬化。
5.未控制的HIV感染，CD4细胞计数＜200/mm³。
6.实体肿瘤。
对于具备至少一项相应体征或症状且至少一项纳入标准的患者，符合以下至少一项临床标准和至少一项真菌学标准即可临床诊断为IPA或TBA：
1.临床标准
(1)支气管镜检查发现气管支气管溃疡、结节、假膜、斑块和/或焦痂（用于诊断临床诊断TBAb）
(2)胸部CT显示肺部浸润影和/或空洞形成，且无法用其他原因解释（用于诊断临床诊断IPA）
2.真菌学标准
(1)支气管肺泡灌洗液（BALF）曲霉培养阳性
(2)血清半乳甘露聚糖（GM）＞0.5光密度指数（ODI）c
(3)BALF半乳甘露聚糖≥1.0 ODIc,d
缩写：BALF：支气管肺泡灌洗液；COPD：慢性阻塞性肺疾病；COVID-19：2019冠状病毒病；CT：计算机断层扫描；HIV：人类免疫缺陷病毒；ICU：重症监护病房；IPA：侵袭性肺曲霉病；ODI：光密度指数；PCR：聚合酶链反应；TBA：气管支气管曲霉病。
a 评估临床诊断IPA/TBA时，机械通气超过48小时的患者不适用；若开始通气时即存在呼吸困难，则在通气后48小时内适用。b 对于COVID-19或流感患者，即使无相应体征和症状，若同时满足以下两项也可诊断为临床诊断TBA：（i）支气管镜检查发现气管支气管溃疡、结节、假膜、斑块和/或焦痂；（ii）任何一项真菌学标准阳性。c 使用Platelia曲霉抗原检测试剂盒。d 若无法获取Platelia检测试剂盒，可使用其他半乳甘露聚糖检测方法，但该方法需经过良好设计的研究验证，且特异性与Platelia检测试剂盒的1.0临界值相当。表2：重症监护病房患者念珠菌血症治疗方案
临床场景
推荐一线治疗方案
替代治疗方案
备注
初始目标治疗
棘白菌素类（卡泊芬净、米卡芬净、阿尼芬净或瑞萨芬净）a
脂质体两性霉素B或氟康唑（若菌株敏感且耐药风险低）
棘白菌素类因广谱抗菌活性、杀真菌作用和良好的安全性，仍是首选治疗方案。瑞萨芬净因每周给药一次且对念珠菌属活性强，现已被纳入一线治疗选项。
降阶梯治疗
氟康唑（若菌株敏感、患者病情稳定、血培养转阴、感染源控制充分）
伏立康唑或泊沙康唑（若对氟康唑耐药）
临床改善且微生物学清除后，尽早转为口服唑类药物（治疗≥5天后）可减少导管相关并发症和治疗成本。仅在临床改善和微生物学清除后进行降阶梯治疗。
中枢神经系统/眼部受累；棘白菌素类或唑类耐药菌株感染
脂质体两性霉素B ±氟胞嘧啶脂质体两性霉素B
大剂量氟康唑或伏立康唑（若敏感）；福沙康唑或艾沙康唑（若可用）
棘白菌素类穿透性差，因此不推荐用于中枢神经系统/眼部感染。难治性病例可考虑联合治疗。需实施感染控制和抗真菌药物管理措施。
治疗疗程
首次血培养转阴且症状缓解后至少治疗14天
-
通常不推荐短疗程治疗；观察性研究表明，在部分“非复杂性念珠菌血症”病例中短疗程治疗可能安全，但需经随机对照试验验证。
感染源控制
-
-
是治疗的关键环节：移除血管内导管、引流脓肿、处理腹腔感染病灶。
缩写：CNS：中枢神经系统；LD：负荷剂量；RCT：随机对照试验。
a 棘白菌素类药物剂量：卡泊芬净70mg负荷剂量，之后50mg每日一次；米卡芬净100mg每日一次；阿尼芬净200mg负荷剂量，之后100mg每日一次；瑞萨芬净400mg每周一次；氟康唑400-800mg每日一次；脂质体两性霉素B 3-5mg/kg每日一次。表3：重症监护病房患者侵袭性肺曲霉病治疗药物
药物
适应症
标准剂量方案
优势
局限性
TDM
伏立康唑
一线治疗
6mg/kg静脉注射，每12小时一次，共2剂；之后4mg/kg静脉注射/口服，每12小时一次
疗效证据充分，可静脉/口服转换
药代动力学非线性，个体差异大，存在肝毒性和神经毒性等不良反应风险
是
艾沙康唑
一线替代治疗
372mg（硫酸艾沙康唑，相当于200mg艾沙康唑），每8小时一次，共6剂；之后372mg静脉注射/口服，每日一次
疗效不劣于伏立康唑，不良反应和药物相互作用更少，无需常规TDM
ICU患者中药代动力学变异大，肥胖/重症患者可能出现亚治疗剂量
考虑
泊沙康唑
补救治疗/替代治疗
第1天300mg静脉注射/口服，每12小时一次；之后300mg每日一次
一项试验显示疗效不劣于伏立康唑，对高危患者有预防疗效
在侵袭性曲霉病中应用有限（主要用于预防/补救治疗）
是
脂质体两性霉素B（L-AmB）
替代治疗（唑类耐药/不耐受）
3-5mg/kg静脉注射，每日一次
对耐药菌株有效，应用经验成熟
存在肾毒性、电解质紊乱风险
否
棘白菌素类（卡泊芬净、米卡芬净、阿尼芬净）
补救治疗/联合治疗
卡泊芬净：70mg静脉注射负荷剂量，之后50mg每日一次；米卡芬净：100mg静脉注射每日一次；阿尼芬净：200mg静脉注射负荷剂量，之后100mg每日一次
安全性良好，适用于难治性疾病，可作为辅助治疗
单药疗效欠佳，ICU中数据有限
否
缩写：IA：侵袭性曲霉病；ICU：重症监护病房；IV：静脉注射；LD：负荷剂量；TDM：治疗药物监测。表4：处于临床开发阶段的侵袭性曲霉病新型抗真菌药物
药物
作用机制
研究剂量
开发阶段
潜在优势
当前局限性
奥罗菲姆
抑制二氢乳清酸脱氢酶（DHODH）
口服90mg，每12小时一次（II/III期研究）；静脉制剂正在评估中
III期
对唑类和两性霉素B耐药的曲霉属真菌活性强，组织和中枢神经系统（CNS）穿透性好
静脉制剂数据有限，经CYP3A4代谢存在药物相互作用风险
福沙康唑（马诺匹克斯前体药物）
抑制Gwt1（糖基磷脂酰肌醇锚定生物合成）
口服/静脉注射：1000mg负荷剂量，之后600mg每日一次（试验方案）
III期
广谱抗菌活性（覆盖霉菌和酵母菌），包括唑类耐药烟曲霉
临床经验有限
奥培康唑（PC945，吸入性三唑类）
抑制麦角固醇生物合成（局部给药）
吸入给药；研究剂量正在进行中
II期（NCT05238116）
肺部浓度高，全身毒性低
处于试验阶段，无全身覆盖作用
艾沙康唑
葡聚糖合酶抑制剂（三萜类）
口服750-1500mg每日一次（研究中）
II/III期
对唑类耐药曲霉有活性，口服生物利用度高
曲霉病数据有限（主要针对念珠菌病）
缩写：CNS：中枢神经系统；IA：侵袭性曲霉病；IV：静脉注射。表5：重症监护病房患者耶氏肺孢子菌肺炎治疗方案
药物
治疗线别/适应症
剂量和给药方式
疗程
联合用药/备注
TMP/SMX
所有患者（HIV和非HIV感染）一线治疗
TMP 15-20mg/kg/日 + SMX 75-100mg/kg/日，静脉注射或口服，每6-8小时一次分剂给药
21天
监测肾功能、血钾和血液毒性。肾功能不全时调整剂量。
戊烷脒（静脉注射）
TMP/SMX不耐受或禁忌时的二线选择
4mg/kg静脉注射，每日一次（输注时间≥60分钟）
21天
监测肾毒性、电解质紊乱、胰腺炎、低血糖/高血糖。胰腺移植受者避免使用。
克林霉素 + 伯氨喹（口服）
TMP/SMX不耐受时的替代方案
克林霉素600mg口服/静脉注射，每6小时一次，或900mg静脉注射，每8小时一次 + 伯氨喹15-30mg口服，每日一次
21天
使用前检查葡萄糖-6-磷酸脱氢酶（G6PD）状态（存在溶血风险）。监测血液学指标。
阿托伐醌（口服）
TMP/SMX不耐受时轻中度肺孢子菌肺炎替代方案
750mg口服，每日两次，与高脂餐同服以提高吸收
21天
耐受性良好；生物利用度变异大；不推荐用于重症疾病。
氨苯砜 + 甲氧苄啶（口服）
轻症患者的替代口服方案
氨苯砜100mg口服，每日一次 + TMP 20mg/kg/日，每6-8小时一次分剂给药
21天
G6PD缺乏患者避免使用；监测溶血性贫血。
TMP/SMX + 棘白菌素类（如卡泊芬净）
重症或难治性肺孢子菌肺炎的联合/补救治疗，尤其适用于ICU患者
TMP/SMX剂量同上 + 卡泊芬净50mg静脉注射，每日一次（70mg负荷剂量后）
21天（视情况而定）
具有潜在协同作用；可能改善重症非HIV感染患者的临床反应。证据来自回顾性研究；尚无随机对照试验。
辅助糖皮质激素（HIV阳性患者）
中重度疾病（动脉血氧分压PaO2＜70mmHg或肺泡-动脉氧梯度A-a＞35mmHg）
泼尼松口服：40mg每日两次×5天 → 40mg每日一次×5天 → 20mg每日一次×11天（总疗程21天），或甲基泼尼松龙静脉注射（口服剂量的80%）
21天
应在启动抗菌治疗后72小时内开始；可降低死亡率和机械通气需求。
辅助糖皮质激素（HIV阴性患者）
目前关于其获益尚无明确结论
甲基泼尼松龙30mg静脉注射，每日两次×5天 → 30mg每日一次×5天 → 20mg每日一次至第21天（用于随机对照试验）
21天
近期随机对照试验显示，非HIV重症患者使用无死亡率获益，但研究组间绝对死亡率差异的幅度可能仍需进一步研究。
缩写：A-a梯度：肺泡-动脉氧梯度；BID：每日两次；G6PD：葡萄糖-6-磷酸脱氢酶；HIV：人类免疫缺陷病毒；ICU：重症监护病房；IV：静脉注射；PaO2：动脉血氧分压；PO：口服；PjP：耶氏肺孢子菌肺炎；q6-8h：每6-8小时一次；QD：每日一次；RCT：随机对照试验；TMP-SMX：甲氧苄啶-磺胺甲恶唑。
【诊疗方案】免疫抑制宿主重症肺炎诊断与治疗专家共识
《英国医学真菌学会严重真菌病诊断最佳实践建议：2025年更新》详细总结
超越指南：处理真菌诊断时我需要了解什么？
微生物疗法临床研究
2026-04-03
Journal of Antimicrobial Chemotherapy Volume 81, Issue 1抗菌化疗杂志81卷 1期
https://academic.oup.com/jac/issue
50th Anniversary Collection
50周年纪念合集
Review（综述）
1
Artificial intelligence for improving decision-making in bacterial infection management: a narrative review
人工智能在改善细菌感染治疗决策中的应用：一项叙述性综述
Anisia Talianu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf470, https://doi.org/10.1093/jac/dkaf470
Reviews（综述）
2
Evolving landscape of methicillin-resistant Staphylococcus pseudintermedius: the emergence of new epidemic waves across Europe, Asia and North America
耐甲氧西林中间型葡萄球菌的演变格局：欧洲、亚洲和北美洲新流行浪潮的出现
Lillian Rose Giarratana and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf340, https://doi.org/10.1093/jac/dkaf340
3
Azithromycin resistance in non-typhoidal Salmonella: a review
非伤寒沙门氏菌对阿奇霉素的耐药性：综述
Zhe Zhu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf341, https://doi.org/10.1093/jac/dkaf341
4
Antibiotic pharmacodynamics: from MIC to advanced metrics and their applications
抗生素药效动力学：从最低抑菌浓度到高级指标及其应用
Malin Andersson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf374, https://doi.org/10.1093/jac/dkaf374
5
Progress in the study of drug resistance mechanism of Bacillus cereus
蜡样芽孢杆菌耐药机制研究进展
Yuhang Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf399, https://doi.org/10.1093/jac/dkaf399
6
The curious constraints on clofazimine
氯法齐明的奇特限制
Maple Goh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf430, https://doi.org/10.1093/jac/dkaf430
7
Antiplasmid systems: a novel strategy to combat antibiotic resistance
抗质粒系统：对抗抗生素耐药性的新策略
Mohd Asim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf472, https://doi.org/10.1093/jac/dkaf472
Systematic Review（系统综述）
8
Coccidioidomycosis in Europe: a systematic literature review of epidemiology, treatment and outcomes
欧洲球孢子菌病：流行病学、治疗和预后的系统文献综述
Priya Shastri and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf407, https://doi.org/10.1093/jac/dkaf407
9
Systematic review of antimicrobial pharmacokinetic/pharmacodynamic indices in murine thigh and hollow fibre dose fractionation studies analysed with a standard method
用标准方法分析小鼠大腿和空心纤维剂量分次研究中的抗菌药物药代动力学/药效动力学指数的系统综述
Najla Alabdulkarim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf446, https://doi.org/10.1093/jac/dkaf446
Virtual Roundtable（虚拟圆桌会议）
10
Procalcitonin in the management of lower respiratory tract infection and sepsis
降钙素原在下呼吸道感染和败血症治疗中的应用
Ramy H Elshaboury and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf298, https://doi.org/10.1093/jac/dkaf298
Original Research（论著）
11
Model-based assessment of letermovir pharmacokinetics in allogeneic haematopoietic stem cell transplant recipients
来特莫韦在异基因造血干细胞移植受者中药代动力学的基于模型的评估
Chrisoula Tahtsidou and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf427, https://doi.org/10.1093/jac/dkaf427
12
In vitro exebacase (CF-301) activity against methicillin-susceptible or methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci strains isolated from patients with infective endocarditis
体外试验评估依拉环素（CF-301）对甲氧西林敏感或甲氧西林耐药金黄色葡萄球菌及凝固酶阴性葡萄球菌（从感染性心内膜炎患者中分离）的活性
María-Alexandra Cañas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf435, https://doi.org/10.1093/jac/dkaf435
13
Evaluation of subcutaneous amoxicillin/clavulanic acid pharmacokinetics as an alternative to the intravenous route in older patients—the PhASAge Study
评估皮下注射阿莫西林/克拉维酸药代动力学作为老年患者静脉给药替代方案——PhASAge研究
Nicolas Grégoire and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf381, https://doi.org/10.1093/jac/dkaf381
14
Real-life use of isavuconazole in Spanish children and adolescents
西班牙儿童和青少年中艾沙康唑的实际使用情况
Natalia Mendoza-Palomar and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf394, https://doi.org/10.1093/jac/dkaf394
15
No pharmacovigilance signal of intracranial hypertension associated with glycylcyclines: a FAERS-based disproportionality analysis
基于FAERS数据库的不成比例性分析：未发现甘氨酰环素类与颅内高压相关的药物警戒信号
Slobodan M Jankovic and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf395, https://doi.org/10.1093/jac/dkaf395
16
Posaconazole enteral tube administration in adults: pharmacokinetic target attainment of oral suspension compared with crushed delayed-release tablet
成人经肠内营养管给予泊沙康唑：口服混悬液与碾碎的缓释片的药代动力学目标达成情况比较
Nirjan Bhattarai and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf396, https://doi.org/10.1093/jac/dkaf396
17
Characterizing CYP3A4-mediated drug interactions: a fixed-sequence pharmacokinetic Chinese study of posaconazole and ruxolitinib in haematological malignancies
CYP3A4介导的药物相互作用特征：一项关于泊沙康唑和鲁索替尼在血液系统恶性肿瘤中的固定序列药代动力学中国研究
Beibei Liang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf398, https://doi.org/10.1093/jac/dkaf398
18
Differences in prescription for impetigo and cellulitis across years in three European countries
三个欧洲国家不同年份脓疱病和蜂窝织炎的处方差异
Thomas Bettuzzi and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf400, https://doi.org/10.1093/jac/dkaf400
19
β-Lactam concentrations monitored in the early phase of community-acquired sepsis in the intensive care unit
重症监护室社区获得性脓毒症早期阶段监测的β-内酰胺浓度
Karolina Liljedahl Prytz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf401, https://doi.org/10.1093/jac/dkaf401
20
Enhanced antimycobacterial efficacy of simulated inhaled clofazimine versus oral clofazimine in combination with azithromycin and ethambutol in a hollow-fiber system
在空心纤维系统中，模拟吸入氯法齐明与口服氯法齐明联合阿奇霉素和乙胺丁醇的抗结核分枝杆菌疗效增强比较
Jelmer Raaijmakers and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf402, https://doi.org/10.1093/jac/dkaf402
21
Identification of antimicrobial resistance genes in Escherichia coli through network diffusion
通过网络扩散法鉴定大肠杆菌中的抗生素耐药基因
Anis Mansouri and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf404, https://doi.org/10.1093/jac/dkaf404
22
Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung disease
依培硼罗在脓肿分枝杆菌肺病空心纤维系统模型中的临床前评估
Sanjay Singh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf405, https://doi.org/10.1093/jac/dkaf405
23
The β-lactamase inhibitor concentration-dependent minimum inhibitory concentration (MICcBLI) as methodology to assess the pharmacokinetic/pharmacodynamic relationship of piperacillin/tazobactam for dosing optimization
β-内酰胺酶抑制剂浓度依赖性最低抑菌浓度（MICcBLI）作为评估哌拉西林/他唑巴坦药代动力学/药效动力学关系以优化给药的方法
Malin Andersson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf406, https://doi.org/10.1093/jac/dkaf406
24
Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction
解析铜绿假单胞菌AmpC诱导过程中青霉素结合蛋白、β-内酰胺酶活性和mRNA动态的三元关系
Maria Montaner and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf408, https://doi.org/10.1093/jac/dkaf408
25
Unnoticed spread of linear VanA-plasmids in vancomycin-variable Enterococcus faecium strains across different regions: a diagnostics challenge
不同地区万古霉素可变型粪肠球菌菌株中线性VanA质粒的未被察觉的传播：一项诊断挑战
Ana C Almeida-Santos and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf409, https://doi.org/10.1093/jac/dkaf409
26
Switching from etravirine to doravirine in virologically suppressed people with HIV: results from the French multicentre SWEED observational study
在病毒学抑制的HIV感染者中从依曲韦林切换至多拉韦林：法国多中心SWEED观察性研究的结果
Romain Palich and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf410, https://doi.org/10.1093/jac/dkaf410
27
HIV-1 drug resistance among pregnant and breastfeeding mothers and its association with paediatric HIV infections in the Dolutegravir era in Uganda
乌干达多替拉韦时代孕产妇及哺乳期母亲中HIV-1耐药情况及其与儿童HIV感染的关联
Anne Kapaata and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf411, https://doi.org/10.1093/jac/dkaf411
28
Outpatient antibiotic prescribing for medically attended respiratory syncytial virus, influenza, or human metapneumovirus illness among high-risk adults in rural Wisconsin, United States
美国威斯康星州农村地区高风险成人因呼吸道合胞病毒、流感或人偏肺病毒感染就诊时的门诊抗生素处方情况
Sarah C J Jorgensen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf412, https://doi.org/10.1093/jac/dkaf412
29
Omadacycline as a drug candidate for Mycobacterium avium infections: in vitro insights on single and combination therapies
奥马环素作为鸟分枝杆菌感染候选药物：单药及联合治疗的体外研究
Saskia E Mudde and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf413, https://doi.org/10.1093/jac/dkaf413
30
Post-pandemic trends in Streptococcus pneumoniae serotype epidemiology and antibiotic susceptibility in adults with invasive and non-invasive pneumococcal disease in the USA (2022–2023)
后疫情时代美国成人侵袭性与非侵袭性肺炎链球菌病血清型流行病学及抗生素敏感性趋势（2022-2023）
Mekki F Bensaci and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf414, https://doi.org/10.1093/jac/dkaf414
31
Benznidazole pharmacokinetics in patients with chronic Chagas disease: association with demographic factors and adverse drug reactions
慢性恰加斯病患者苯芴醇药代动力学：与人口统计学因素及药物不良反应的关联
Gabriel P E Silveira and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf416, https://doi.org/10.1093/jac/dkaf416
32
Acquired antimicrobial resistance genes in Bordetella Species: a global genomic analysis
博德特氏菌属中获得的抗菌药物耐药基因：全球基因组分析
Biao Tang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf418, https://doi.org/10.1093/jac/dkaf418
33
Machine learning for personalized antimicrobial susceptibility breakpoints: (Adaptive clinical breakpoint interpretation)
基于机器学习的个性化抗菌药物敏感性折点制定（自适应临床折点解释）
Yinzheng Zhong and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf419, https://doi.org/10.1093/jac/dkaf419
34
Multicentre investigation of Wickerhamomyces anomalus fungemia in India: emerging resistance and mechanistic insights
印度异常威克汉姆酵母菌血症的多中心研究：新发耐药性及机制洞察
Shristi Verma and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf420, https://doi.org/10.1093/jac/dkaf420
35
Reducing aztreonam/avibactam waste: insights from Monte Carlo simulations
减少氨曲南/阿维巴坦浪费：蒙特卡洛模拟的启示
Yeleen Fromage and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf421, https://doi.org/10.1093/jac/dkaf421
36
Nanoparticle-based co-delivery of ciprofloxacin and meropenem enhances synergistic activity against multidrug-resistant hypervirulent Klebsiella pneumoniae clinical isolates
基于纳米颗粒的环丙沙星与美罗培南共递送可增强对多重耐药高毒力肺炎克雷伯菌临床分离株的协同活性
Reham Mostafa and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf422, https://doi.org/10.1093/jac/dkaf422
37
Development of population pharmacokinetic models of total and free piperacillin in critically ill children and young adults for Monte Carlo simulations and model-informed precision dosing
危重症儿童及青年总游离哌拉西林群体药代动力学模型开发：用于蒙特卡洛模拟及模型引导的精准给药
Sonya Tang Girdwood and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf423, https://doi.org/10.1093/jac/dkaf423
38
Reaching the target: time and dose required to achieve target vancomycin plasma concentrations in admitted patients
达标分析：住院患者达到目标万古霉素血浆浓度所需的时间与剂量
W Töpfer and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf424, https://doi.org/10.1093/jac/dkaf424
39
Notable transmitted HIV drug resistance among people who inject drugs in Pakistan
巴基斯坦注射毒品人群中显著传播的HIV耐药性
Stephanie Melnychuk and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf425, https://doi.org/10.1093/jac/dkaf425
40
Synergistic but clinically unattainable: amoxicillin/ceftriaxone combination against ampicillin-susceptible Enterococcus faecium
协同但临床难以实现：阿莫西林/头孢曲松联合对氨苄西林敏感粪肠球菌的体外活性
Ahmed Ashrin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf426, https://doi.org/10.1093/jac/dkaf426
41
Pharmacodynamic studies of taniborbactam (VNRX-5133) combined with cefepime against β-lactamase–producing Gram-negative bacteria in a neutropenic murine thigh infection model
中性粒细胞减少小鼠大腿感染模型中他尼硼巴坦（VNRX-5133）联合头孢吡肟对产β-内酰胺酶革兰氏阴性菌的药效动力学研究
Panagiota-Christina Georgiou and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf431, https://doi.org/10.1093/jac/dkaf431
42
Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp.
非塞拉蒂亚属肠杆菌目细菌所致心内膜炎的流行病学及治疗
Clayton F Hausberger and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf432, https://doi.org/10.1093/jac/dkaf432
43
Enhanced activity of apramycin and apramycin-based combinations against Mycobacteroides abscessus
阿普拉霉素及其组合对脓肿分枝杆菌的增强活性
Yanqin Huang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf433, https://doi.org/10.1093/jac/dkaf433
44
Efflux-mediated multidrug resistance mechanism in Trichophyton indotineae and Trichophyton rubrum; role of ABC transporters and MFS gene
印度毛癣菌与红色毛癣菌中由ABC转运蛋白和MFS基因介导的流出泵型多重耐药机制
Dipika Shaw and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf434, https://doi.org/10.1093/jac/dkaf434
45
Sphingobacterium spp. as intrinsic producers of SPI Ambler class B metallo-β-lactamases
鞘氨醇杆菌属作为SPI Ambler B类金属β-内酰胺酶的固有产生者
Delphine Girlich and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf436, https://doi.org/10.1093/jac/dkaf436
46
Global phylogeography and genomic characterization of blaNDM-1-positive carbapenem-resistant Acinetobacter soli
blaNDM-1阳性碳青霉烯耐药溶胶阿卡净菌的全球系统发育地理学及基因组特征
Pengpeng Min and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf437, https://doi.org/10.1093/jac/dkaf437
47
Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients
血液透析患者潜伏性结核治疗中每月一次每日利福喷丁的药代动力学及耐受性
Thornthun Ueaphongsukkit and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf439, https://doi.org/10.1093/jac/dkaf439
48
In vitro susceptibility of cefepime-enmetazobactam, cefepime-taniborbactam and cefepime-zidebactam towards carbapenemase-producing Enterobacterales
头孢吡肟-恩美他唑巴坦、头孢吡肟-他尼硼巴坦及头孢吡肟-齐德巴坦对产碳青霉烯酶肠杆菌目的体外敏感性
Marion Dutkiewicz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf440, https://doi.org/10.1093/jac/dkaf440
49
In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates
舒巴坦/杜洛巴坦联合β-内酰胺类抗生素对澳大利亚脓肿分枝杆菌分离株的体外疗效
Kirby Patterson-Fahy and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf441, https://doi.org/10.1093/jac/dkaf441
50
Harnessing CRISPR–Cas9 and CRISPRi systems to reverse antibiotic resistance in a clinical multidrug-resistant Escherichia coli isolate
利用CRISPR-Cas9及CRISPRi系统逆转临床多重耐药大肠杆菌分离株的抗生素耐药性
Ruonan Zhao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf442, https://doi.org/10.1093/jac/dkaf442
51
Cotrimoxazole in the intensive care unit: an impossible task for the fixed association in real life?
重症监护室中复方磺胺甲噁唑的应用：固定组合在现实中的不可行性？
Manon Launay and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf443, https://doi.org/10.1093/jac/dkaf443
52
National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing
哥伦比亚全国代表性调查：基于下一代测序的抗逆转录病毒耐药相关突变分析
Ernesto Martínez-Buitrago and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf444, https://doi.org/10.1093/jac/dkaf444
53
A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimens
基于模型的含固定剂量多替拉韦方案减量策略比较
Laura Dickinson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf445, https://doi.org/10.1093/jac/dkaf445
54
Therapeutic drug monitoring and target attainment of unbound flucloxacillin in hospitalized patients with measured MICs (FLUTE)
住院患者中游离氟氯西林的治疗药物监测及目标达成情况（基于实测最低抑菌浓度的FLUTE研究）
Pjotr P Temme and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf447, https://doi.org/10.1093/jac/dkaf447
55
Nirmatrelvir-ritonavir addition to acute care formulary: a retrospective, multi-centre evaluation of quantitative economic and qualitative clinical outcomes
奈玛特韦/利托那韦纳入急症治疗目录：一项多中心回顾性评估定量经济与定性临床结果的研究
Jose Valdes Ledesma and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf448, https://doi.org/10.1093/jac/dkaf448
56
Local antibiotic resistance surveillance in nursing homes using lot quality assurance sampling: a feasibility study
采用批量质量保证抽样法对养老院进行本地抗生素耐药性监测的可行性研究
Sacha Kuil and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf451, https://doi.org/10.1093/jac/dkaf451
57
High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021–24
2021-2024年，在世卫组织三个区域的八个世卫组织增强淋球菌抗菌药物监测计划国家中，新型抗菌药物吉皮达星对淋病奈瑟菌分离株的体外活性较高
Josefine Ahlstrand and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf452, https://doi.org/10.1093/jac/dkaf452
58
Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stable
尽管整合酶抑制剂用于治疗HIV感染的使用量不断增加，但此类药物的耐药性仍保持稳定
Cathia Soulie and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf454, https://doi.org/10.1093/jac/dkaf454
59
Fine-needle aspiration in infected necrotizing pancreatitis in the delayed intervention era: a post hoc analysis of safety, microbiological yield and therapeutic implications
延迟干预时代感染性坏死性胰腺炎的细针穿刺抽吸术：安全性、微生物学检出率及治疗意义的事后分析
Hannah S Pauw and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf455, https://doi.org/10.1093/jac/dkaf455
60
β-Lactam dosing in critically ill children: predictors for target non-attainment
危重症儿童β-内酰胺类药物给药：未达目标浓度的预测因素
Stef Schouwenburg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf457, https://doi.org/10.1093/jac/dkaf457
61
Co-administration of triazoles with calcineurin or mammalian target of rapamycin inhibitors in solid organ transplant patients hospitalized with invasive aspergillosis
实体器官移植患者合并侵袭性曲霉病住院时三唑类药物与钙调磷酸酶抑制剂或哺乳动物雷帕霉素靶蛋白抑制剂的联合用药情况
Barbara Alexander and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf461, https://doi.org/10.1093/jac/dkaf461
62
In vitro selection of cefiderocol-resistant mutants in Acinetobacter baumannii harbouring the most common carbapenemase genes
携带最常见碳青霉烯酶基因的鲍曼不动杆菌中头孢地尔耐药突变体的体外筛选
Otávio Hallal Ferreira Raro and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf462, https://doi.org/10.1093/jac/dkaf462
63
Preventing resistance development in infections by OXA β-lactamase-producing Pseudomonas aeruginosa: correlating clinical outcomes with hollow-fibre model input
预防产OXA β-内酰胺酶铜绿假单胞菌感染耐药性的产生：将临床结局与中空纤维模型输入相关联
María M Montero and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf464, https://doi.org/10.1093/jac/dkaf464
64
A national pilot community pharmacy–led urinary tract infection service: clinical and patient-reported outcomes from 9077 consultations
全国社区药房主导的尿路感染服务试点项目：9077次咨询的临床结局和患者报告结局
Efi Mantzourani and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf466, https://doi.org/10.1093/jac/dkaf466
65
Towards enhanced translational value: preclinical drug activity testing against actively multiplying, nutrient-starved and pellicle biofilm-embedded Mycobacterium abscessus
提高转化价值：针对活跃增殖、营养匮乏和生物膜包裹的脓肿分枝杆菌进行临床前药物活性测试
Henriëtte M Meliefste and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf468, https://doi.org/10.1093/jac/dkaf468
Research Letters（研究快报）
66
Novel multiresistance transposon Tn7731 in bovine Pasteurella multocida from Germany
德国牛源多杀性巴氏杆菌中新型多重耐药转座子Tn7731
Henrike Krüger-Haker and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf336, https://doi.org/10.1093/jac/dkaf336
67
Efficacy of eravacycline in difficult-to-treat (DTR) Acinetobacter baumannii bacteraemia in ICU: a case report
厄他培南治疗重症监护病房难治性鲍曼不动杆菌菌血症的疗效：一例病例报告
Monica Melchio and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf347, https://doi.org/10.1093/jac/dkaf347
68
Possible increased risk of Epstein–Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients
来特莫韦暴露的造血细胞移植受者中EB病毒感染和移植后淋巴增殖性疾病风险可能增加
Jose F Camargo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf348, https://doi.org/10.1093/jac/dkaf348
69
Dalbavancin dosing in a severely underweight woman with prosthetic valve endocarditis: the critical role of proactive therapeutic drug monitoring
达巴万星在严重体重不足人工瓣膜心内膜炎女性患者中的给药：主动治疗药物监测的关键作用
Ambra Barco and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf365, https://doi.org/10.1093/jac/dkaf365
70
Cefazolin-induced seizures in a haemodialysis patient with elevated serum and cerebrospinal fluid concentrations: a case report
血液透析患者头孢唑林血清和脑脊液浓度升高诱发癫痫：一例病例报告
Kohei Hasegawa and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf373, https://doi.org/10.1093/jac/dkaf373
71
Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes
使用聚丙烯腈膜进行连续性肾脏替代治疗的患者中卡泊芬净药代动力学治疗监测的回顾性分析
Antoine Hérault and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf390, https://doi.org/10.1093/jac/dkaf390
72
Diffusion of OXA-48- and NDM-5-producing Klebsiella pneumoniae ST383 clone in Central Italy
产OXA-48和NDM-5的肺炎克雷伯菌ST383克隆在意大利中部的传播
Gloria D’Achille and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf397, https://doi.org/10.1093/jac/dkaf397
73
Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry
来那卡帕韦在病毒载量阳性且接受过大量抗逆转录病毒治疗的HIV感染者中的持久性：来自PRESTIGIO登记处的现实数据
Tommaso Clemente and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf415, https://doi.org/10.1093/jac/dkaf415
74
Co-carriage of the oxazolidinone resistance genes cfr and optrA in a linezolid-resistant Staphylococcus rostri isolate from a pig-farm worker
猪场工人利奈唑胺耐药猪鼻支原体分离株中噁唑烷酮类耐药基因cfr和optrA的共携带情况
Gi Yong Lee and Soo-Jin Yang
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf428, https://doi.org/10.1093/jac/dkaf428
75
Importance of reviewing the package insert from gradient strip manufacturers
梯度扩散法药敏纸片生产商说明书审阅的重要性
Mandy Wootton and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf429, https://doi.org/10.1093/jac/dkaf429
76
One resistance gene, many transposons: repeated formation of compound and pseudo-compound transposons carrying the aphA1 kanamycin and neomycin resistance gene
一个耐药基因，多个转座子：携带aphA1卡那霉素和新霉素耐药基因的复合及假复合转座子的重复形成
Christopher J Harmer and Ruth M Hall
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf450, https://doi.org/10.1093/jac/dkaf450
77
Absence of lymphogranuloma venereum among men who have sex with men on PrEP receiving doxycycline postexposure prophylaxis
接受暴露后多西环素预防性治疗的暴露前预防用药男男性行为者中未发现性病淋巴肉芽肿
Cristina Gómez-Ayerbe and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf456, https://doi.org/10.1093/jac/dkaf456
78
In vitro activity of gepotidacin against Chlamydia trachomatis
吉皮达星对沙眼衣原体的体外活性
Arabella Touati and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf460, https://doi.org/10.1093/jac/dkaf460
Journal of Antimicrobial Chemotherapy Volume 81, Issue 2抗菌化疗杂志 81卷 2期
https://academic.oup.com/jac/issue
Viewpoints（观点）
1
Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?
长效糖肽类：最需要它们的患者获取药物的障碍有哪些，如何克服？
Aleece MacPhail and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf471, https://doi.org/10.1093/jac/dkaf471
2
Redefining antifungal prophylaxis in acute leukaemia in the era of targeted therapies
靶向治疗时代急性白血病抗真菌预防的重新定义
Marcio Nucci and Johan Maertens
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag010, https://doi.org/10.1093/jac/dkag010
Reviews（综述）
3
Research progress on resistance mechanisms and clinical efficacy of tigecycline against Klebsiella pneumoniae
替加环素对肺炎克雷伯菌的耐药机制及临床疗效研究进展
Meilin Wu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf504, https://doi.org/10.1093/jac/dkaf504
4
Liposomal amphotericin B and renal safety: review of the evidence and clinical considerations
两性霉素B脂质体与肾脏安全性：证据回顾及临床考量
Johan Maertens and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf473, https://doi.org/10.1093/jac/dkaf473
5
Strategies for mitigating severe COVID-19 in patients with haematological malignancy during the omicron era
奥密克戎时代减轻血液系统恶性肿瘤患者严重新冠肺炎的策略
Keiji Okinaka and Joshua T Schiffer
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf489, https://doi.org/10.1093/jac/dkaf489
Systematic Reviews（系统综述）
6
Safety and efficacy of gepotidacin in urinary tract infection: a GRADE-assessed systematic review and meta-analysis
吉泊替达辛治疗尿路感染的安全性和有效性：一项基于GRADE评估的系统综述和荟萃分析
Taha Ibrahim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf469, https://doi.org/10.1093/jac/dkaf469
7
The emerging clinical relevance and antimicrobial resistance of Pluralibacter gergoviae: a systematic review
产吲哚金黄杆菌日益凸显的临床相关性和抗菌药物耐药性：一项系统综述
Bruna Abdul Ahad Saad and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf476, https://doi.org/10.1093/jac/dkaf476
8
A comprehensive analysis of the mutational landscape determining polymyxin resistance in Klebsiella pneumoniae
决定肺炎克雷伯菌多粘菌素耐药性的突变谱综合分析
Sambit Kumar Dwibedy and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf503, https://doi.org/10.1093/jac/dkaf503
9
Factors promoting or hindering self-administered outpatient parenteral antimicrobial therapy: a systematic literature review
促进或阻碍自我给药门诊静脉注射抗菌药物治疗的因素：一项系统文献综述
Hester H Stoorvogel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf490, https://doi.org/10.1093/jac/dkaf490
Original Research（论著）
10
Cefepime/enmetazobactam for Gram-negative periprosthetic joint infections? A randomized porcine study on target tissue pharmacokinetics
头孢吡肟/恩美唑巴坦治疗革兰氏阴性假体周围关节感染？一项关于猪的靶组织药代动力学的随机研究
M B D Nielsen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf487, https://doi.org/10.1093/jac/dkaf487
11
Impact of extracorporeal membrane oxygenation modes on voriconazole exposure in critically ill patients
体外膜肺氧合模式对危重患者伏立康唑暴露的影响
Xinrui Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf501, https://doi.org/10.1093/jac/dkaf501
12
Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants
基于模型通过成人和婴儿群体药代动力学-药效学模型评估VRC07-523LS在婴儿中的给药方案
Dustin Huynh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf449, https://doi.org/10.1093/jac/dkaf449
13
Antibiotic resistance of Pseudomonas aeruginosa strains—intracellular metabolomics analysis
铜绿假单胞菌菌株的抗生素耐药性——细胞内代谢组学分析
Karolina Anna Mielko-Niziałek and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf453, https://doi.org/10.1093/jac/dkaf453
14
In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates
头孢吡肟/齐多巴坦对舒巴坦/杜洛巴坦敏感和耐药鲍曼不动杆菌临床分离株的体外活性
Carlo Tascini and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf467, https://doi.org/10.1093/jac/dkaf467
15
Prevalence of macrolide resistance in Mycoplasma pneumoniae in The Netherlands
荷兰肺炎支原体大环内酯类抗生素耐药性的流行情况
Patrick D J Sturm and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf475, https://doi.org/10.1093/jac/dkaf475
16
Simulated lung exposure in pneumonia patients to evaluate the antibacterial capacity and resistance suppression of clinical tigecycline regimens against carbapenem-resistant
Acinetobacter baumannii
模拟肺炎患者肺部暴露情况以评估临床替加环素方案对碳青霉烯类耐药鲍曼不动杆菌的抗菌能力和耐药抑制作用
Xiaonan Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf477, https://doi.org/10.1093/jac/dkaf477
17
Enterococcus faecium harbouring vanA, optrA and cfr(D) on a linear plasmid in Canada: a CANWARD surveillance case
加拿大发现携带vanA、optrA和cfr(D)的粪肠球菌线性质粒：一项CANWARD监测病例
Melissa McCracken and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf478, https://doi.org/10.1093/jac/dkaf478
18
The effect of intrauterine exposure to aminoglycosides on neonatal hearing
宫内暴露于氨基糖苷类抗生素对新生儿听力的影响
Daniel Leshin-Carmel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf483, https://doi.org/10.1093/jac/dkaf483
19
Ceftazidime/avibactam: a potent arsenal against multidrug-resistant Pseudomonas aeruginosa-unveiling in vitro and in vivo strategies
头孢他啶/阿维巴坦：对抗多重耐药铜绿假单胞菌的有力武器——揭示体内外策略
Jiaju Zhuo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf495, https://doi.org/10.1093/jac/dkaf495
20
Comparison of disk diffusion, MIC test strip and broth microdilution for eravacycline susceptibility testing of 422 Staphylococcus aureus isolates using ChinaCAST breakpoints
采用中国CAST折点，比较422株金黄色葡萄球菌对依拉环素的纸片扩散法、最低抑菌浓度测试条法和肉汤微量稀释法的敏感性测试结果
Xinying Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf502, https://doi.org/10.1093/jac/dkaf502
21
Penetration of daptomycin in cerebrospinal fluid during pneumococcal meningitis
肺炎链球菌性脑膜炎期间达托霉素在脑脊液中的渗透情况
Pascal Chavanet and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf474, https://doi.org/10.1093/jac/dkaf474
22
Rapid molecular diagnostics for detection of extensively drug-resistant Salmonella Typhi
用于检测广泛耐药伤寒沙门菌的快速分子诊断技术
Emma L Sweeney and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf481, https://doi.org/10.1093/jac/dkaf481
23
Gender inequality and antibiotic consumption: analysis of pharmaceutical sales data from 70 countries, 2000–22
性别不平等与抗生素消费：基于2000 - 2022年70个国家药品销售数据的分析
Deepshikha Batheja and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag002, https://doi.org/10.1093/jac/dkag002
24
Real-world evaluation of isavuconazole in children with cancer
伊沙康唑在儿童癌症患者中的现实应用评估
Janine Nijhuis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf485, https://doi.org/10.1093/jac/dkaf485
25
Assessing antimicrobial susceptibility testing guideline adherence by laboratories providing bacteriology services in Ghana: a pilot study
加纳提供细菌学服务的实验室对抗菌药物敏感性试验指南依从性的评估：一项试点研究
Joseph Elikem Efui Acolatse and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag003, https://doi.org/10.1093/jac/dkag003
26
Resistance to second-generation integrase inhibitors in people with HIV following treatment failure on dolutegravir- or bictegravir-based ART in Taiwan
台湾地区基于多替拉韦或比克替拉韦的抗逆转录病毒治疗失败后，HIV感染者对第二代整合酶抑制剂的耐药性
Guan-Jhou Chen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf488, https://doi.org/10.1093/jac/dkaf488
27
In vitro activity of gepotidacin against a challenging panel of multidrug-resistant Neisseria gonorrhoeae isolates
吉泊西汀对一组具有挑战性的多重耐药淋病奈瑟菌分离株的体外活性
Michelle Jayne Cole and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag001, https://doi.org/10.1093/jac/dkag001
28
A disproportionality analysis of adverse events associated with omadacycline based on the FDA adverse event reporting system database
基于美国食品药品监督管理局（FDA）不良事件报告系统数据库的奥马环素相关不良事件比例失衡分析
Ye-Lei Zhao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag006, https://doi.org/10.1093/jac/dkag006
29
Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis
基于体重范围的口服异速缩放米替福新给药方案在儿童内脏利什曼病患者中的简化应用
Andres Mazariegos Herrera and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag014, https://doi.org/10.1093/jac/dkag014
30
evelopment of a capability framework for antimicrobial stewardship specialist health professionals working in the NHS in England: utilizing Delphi methodology
运用德尔菲法为在英国国家医疗服务体系（NHS）中工作的抗菌药物管理专业人员制定能力框架
Ryan A Hamilton and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf438, https://doi.org/10.1093/jac/dkaf438
31
First characterization of insertions in the HIV-1 integrase-coding region from people with HIV
首次对来自艾滋病病毒感染者的HIV-1整合酶编码区插入情况进行特征分析
Nhat Quang Tu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf491, https://doi.org/10.1093/jac/dkaf491
32
Development of an impedance-based fast antimicrobial susceptibility test for Neisseria gonorrhoeae
开发一种基于阻抗的淋病奈瑟菌快速抗菌药物敏感性检测方法
Caitlin N Daniels and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf493, https://doi.org/10.1093/jac/dkaf493
33
Juvenile toxicity and developmental safety of Zintrodiazine, a novel antimalarial candidate, in Wistar rats
新型抗疟候选药物Zintrodiazine在Wistar大鼠中的幼年毒性和发育安全性研究
Hitesh A Kadu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag008, https://doi.org/10.1093/jac/dkag008
34
Do the redefined EUCAST susceptibility categories warrant adjustment of paediatric antibiotic dosages? Pragmatic physiologically based pharmacokinetic modelling of four commonly used agents
欧洲抗微生物药物敏感性试验委员会（EUCAST）重新定义的敏感性分类是否需要调整儿童抗生素剂量？——对四种常用药物的实用生理药代动力学建模研究
Marika A de Hoop-Sommen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf463, https://doi.org/10.1093/jac/dkaf463
35
Exploring the opportunity for therapeutic drug monitoring (TDM) and precision dose antimicrobials in an outpatient antimicrobial therapy (OPAT) service: a prospective observational study
门诊抗菌治疗（OPAT）服务中开展治疗药物监测（TDM）和精准剂量抗菌治疗的机遇：一项前瞻性观察研究
R C Wilson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf484, https://doi.org/10.1093/jac/dkaf484
36
Impact of sex, age and body composition on rilpivirine and cabotegravir trough concentrations in people with HIV receiving long-acting injectable antiretroviral therapy
性别、年龄和身体成分对接受长效注射用抗逆转录病毒治疗的HIV感染者利匹韦林和卡博特韦谷浓度的影响
Maria Vittoria Cossu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag024, https://doi.org/10.1093/jac/dkag024
37
Pharmacokinetics of cefiderocol during prolonged intermittent kidney replacement therapy in two patients with septic shock
头孢地尔在两例感染性休克患者长时间间歇性肾脏替代治疗期间的药代动力学
Julius J Schmidt and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf496, https://doi.org/10.1093/jac/dkaf496
38
Understanding mechanisms of reduced cefiderocol susceptibility in pvdS and fecI mutants of Pseudomonas aeruginosa
了解铜绿假单胞菌pvdS和fecI突变体对头孢地尔敏感性降低的机制
Yoshinori Yamano and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag004, https://doi.org/10.1093/jac/dkag004
39
Biomarker-informed PBPK modelling of meropenem in paediatric severe pneumonia: implications for target-site PK/PD
基于生物标志物的美罗培南在儿童重症肺炎中的生理药动学模型构建：对靶部位药代动力学/药效学的影响
Yao Liu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf500, https://doi.org/10.1093/jac/dkaf500
40
Evaluating hypoalbuminaemia thresholds associated with delayed blood sterilization among patients receiving cefazolin or antistaphylococcal penicillins for MSSA bacteraemia
评估接受头孢唑林或抗葡萄球菌青霉素治疗甲氧西林敏感金黄色葡萄球菌（MSSA）菌血症患者中，与血液延迟灭菌相关的低白蛋白血症阈值
Sunish Shah and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf498, https://doi.org/10.1093/jac/dkaf498
Research Letters（研究快讯）
41
False-negative result in fourth-generation HIV screening tests after weak detection of p24 antigen in the context of inappropriate post-exposure prophylaxis use: a case report
不当使用暴露后预防用药导致第四代HIV筛查试验p24抗原弱检出后出现假阴性结果：一例病例报告
J Kimmerlin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf459, https://doi.org/10.1093/jac/dkaf459
42
Proposal for the nomenclature of tmexCD-toprJ-like gene clusters
关于tmexCD-toprJ样基因簇命名的建议
Chengzhen Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf482, https://doi.org/10.1093/jac/dkaf482
43
IS26-mediated chromosomal integration of virulence plasmid fragments in ST2237 carbapenem-resistant Klebsiella pneumoniae
IS26介导的毒力质粒片段在ST2237型碳青霉烯耐药肺炎克雷伯菌染色体中的整合
Yan Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag018, https://doi.org/10.1093/jac/dkag018
Letter to the Editor（致编辑的信）
44
Comment on: Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes
对“采用聚丙烯腈膜对接受连续性肾脏替代治疗的患者进行卡泊芬净药代动力学监测的回顾性分析”的评论
Gwénola Marais and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf465, https://doi.org/10.1093/jac/dkaf465
45
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy-right-to-reply
意大利米兰地区使用多西环素暴露后预防（DoxyPEP）人群中，用于治疗细菌性传播感染的抗菌药物使用情况——回应说明
Angelo Roberto Raccagni and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag027, https://doi.org/10.1093/jac/dkag027
ACKNOWLEDGEMENT OF REFEREES（鸣谢审稿专家）
46
Acknowledgement of Referees
鸣谢审稿专家
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf417, https://doi.org/10.1093/jac/dkaf417
CORRECTION（更正）
47
Correction to: Comment on: Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial
更正：关于Evusheld在感染奥密克戎变异株前或奥密克戎变异株的新冠住院患者中的抗病毒效果：对随机DisCoVeRy试验的建模分析的评论
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf492, https://doi.org/10.1093/jac/dkaf492
Journal of Antimicrobial Chemotherapy Volume 81, Issue 3抗菌化疗杂志 81卷 3期
https://academic.oup.com/jac/issue
REVIEW（综述）
1
Closing the PrEP access gap in Europe: a strategic framework for equity and innovation among difficult-to-reach populations
缩小欧洲暴露前预防获取差距：面向难以触及（PrEP）人群的公平与创新战略框架
Josep M Llibre and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag052, https://doi.org/10.1093/jac/dkag052
2
Precision dosing of systemic antifungals in adults: therapeutic drug monitoring, empiric dose optimization and barriers to implementation
成人全身性抗真菌药物的精准给药：治疗药物监测、经验性剂量优化及实施障碍
Daniel B Chastain and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag055, https://doi.org/10.1093/jac/dkag055
3
Bacterial DNA topoisomerase IV and DNA gyrase inhibitors: history of the quinolones, their clinical usage and potential alternatives for the future
细菌DNA拓扑异构酶IV和DNA旋转酶抑制剂：喹诺酮类药物的历史、临床应用及未来潜在替代方案
Daisuke Fukuda and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag054, https://doi.org/10.1093/jac/dkag054
4
Combating multidrug-resistant Klebsiella pneumoniae: current therapeutic regimens and future directions
应对多重耐药肺炎克雷伯菌：当前治疗方案与未来方向
Robiul Islam and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag064, https://doi.org/10.1093/jac/dkag064
SYSTEMATIC REVIEW（系统综述）
5
Global and regional prevalence of metallo-β-lactamases in carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis
耐碳青霉烯类鲍曼不动杆菌中金属β-内酰胺酶的全球和区域流行情况：一项系统综述和荟萃分析
Stamatis Karakonstantis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag037, https://doi.org/10.1093/jac/dkag037
Original Research（论著）
6
The effect of oral ciprofloxacin at conventional doses on the QT interval in a tertiary outpatient setting
三级门诊常规剂量口服环丙沙星对患者QT间期的影响
Weber Liu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag020, https://doi.org/10.1093/jac/dkag020
7
Bictegravir concentrations in breastmilk of healthy, lactating women without HIV
未感染人类免疫缺陷病毒（HIV）的健康哺乳期女性乳汁中的比克替拉韦浓度
L C van der Wekken-Pas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag022, https://doi.org/10.1093/jac/dkag022
8
Management and outcomes of Stenotrophomonas maltophilia recovered from deep-site clinical specimens: a bicentric retrospective cohort study
从深部部位临床标本中分离出的嗜麦芽窄食单胞菌的治疗及转归：一项双中心回顾性队列研究
Anastasia Saade and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag021, https://doi.org/10.1093/jac/dkag021
9
Development of a risk prediction model for vancomycin-associated acute kidney injury: a multicentre retrospective study
万古霉素相关急性肾损伤风险预测模型的建立：一项多中心回顾性研究
Tomoyuki Ishigo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag012, https://doi.org/10.1093/jac/dkag012
10
Cooperation between HIV-1 integrase natural polymorphism K156N and 3′PPT mutations in dolutegravir monotherapy failure
HIV-1 整合酶天然多态性 K156N 与 3′PPT 突变在多替拉韦单药治疗失败中的协同作用
Jolieke A T van Osch and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag033, https://doi.org/10.1093/jac/dkag033
11
Impact of body mass index and serum albumin levels on isavuconazole plasma concentrations in patients with haematological malignancies
体重指数和血清白蛋白水平对血液系统恶性肿瘤患者艾沙康唑血浆浓度的影响
Jie Gao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag032, https://doi.org/10.1093/jac/dkag032
12
Pharmacokinetics of cefotaxime and its metabolite desacetyl-cefotaxime to optimize dosing in critically ill children and children with sickle cell disease
用以优化危重症儿童和镰状细胞病儿童给药剂量的头孢噻肟及其代谢产物去乙酰头孢噻肟的药代动力学研究
Seef Abdalla and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag019, https://doi.org/10.1093/jac/dkag019
13
Summary of ceftriaxone-resistant Neisseria gonorrhoeae in Canada, 2017–24
2017 - 2024年加拿大头孢曲松耐药淋病奈瑟菌情况汇总
Robyn Thorington and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag007, https://doi.org/10.1093/jac/dkag007
14
Improving perioperative prophylactic antibiotic prescribing using a novel decision-support tool
使用新型决策支持工具改进围手术期预防性抗生素处方
Mark Mcintyre and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag015, https://doi.org/10.1093/jac/dkag015
15
Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study
针对产超广谱AmpC酶的阴沟肠杆菌复合群和产气克雷伯菌临床分离株，比较已上市与新一代β-内酰胺类抗生素的抗菌活性：一项多中心研究
Ángel Rodríguez-Villodres and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag034, https://doi.org/10.1093/jac/dkag034
16
Impact of eravacycline on fibrinogen
依拉环素对纤维蛋白原的影响
Emily Stevenson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag030, https://doi.org/10.1093/jac/dkag030
17
Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime–avibactam in a case series of orthotopic liver transplant recipients
原位肝移植受者连续输注头孢他啶-阿维巴坦的药代动力学/药效学胆系分析：一项病例系列研究
Milo Gatti and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag009, https://doi.org/10.1093/jac/dkag009
18
Autoaggregation-associated carbapenem tolerance mediated by mrkH inactivation identified from a cohort of Klebsiella pneumoniae species complex clinical isolates
从肺炎克雷伯菌复合群临床分离株队列中鉴定出由mrkH失活介导的与自动聚集相关的碳青霉烯耐受性
Natsuki Yamanaka and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag017, https://doi.org/10.1093/jac/dkag017
19
In vitro activity of double and triple antimicrobial combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm
双联和三联抗菌药物组合对碳青霉烯耐药铜绿假单胞菌生物膜的体外活性研究
Si-Ho Kim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag031, https://doi.org/10.1093/jac/dkag031
20
LYSC98 as a novel vancomycin-derived agent effective against antibiotic-resistant pathogens in tolerant state
LYSC98作为一种新型万古霉素衍生物，对耐受状态下的耐药病原体有效
Xing Xia and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag036, https://doi.org/10.1093/jac/dkag036
21
HBV status modulates transaminase decrease after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV
HIV感染者从富马酸替诺福韦二吡呋酯切换为丙酚替诺福韦后，HBV状态对转氨酶下降的调节作用
Giuseppe Lapadula and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag045, https://doi.org/10.1093/jac/dkag045
22
Pharmacokinetics of colistin in adult critically ill patients in South Africa
南非成人危重症患者中多黏菌素的药代动力学研究
Veshni Pillay-Fuentes Lorente and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag011, https://doi.org/10.1093/jac/dkag011
23
Antifungal susceptibility surveillance of clinical moulds to olorofim, manogepix, amphotericin B, triazoles and echinocandins at 10 tertiary hospitals in China (2019–24)
2019 - 2024年中国10家三级医院临床霉菌对奥罗芬净、马诺盖匹克斯、两性霉素B、三唑类和棘白菌素类抗真菌药的敏感性监测
Su Chen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag016, https://doi.org/10.1093/jac/dkag016
24
Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study
短周期每周三日依非韦伦/恩曲他滨/富马酸替诺福韦二吡呋酯疗法：一项为期七年的延长研究
Beatriz Borjabad and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag040, https://doi.org/10.1093/jac/dkag040
25
Risk of hypertension in people with HIV in the USA initiating modern antiretroviral regimens: pooled analysis of blood pressure data from five clinical trials
美国感染HIV者启动现代抗逆转录病毒治疗方案后患高血压的风险：五项临床试验血压数据汇总分析
Priscilla Y Hsue and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag005, https://doi.org/10.1093/jac/dkag005
26
Real-world drug monitoring of dalbavancin using a three-dose regimen of 1500mg at days 1, 15 and 43 in bone and joint or cardiovascular infection
采用第1、15和43天各1500毫克的三剂量方案对达巴万星（Dalbavancin）在骨关节或心血管感染治疗中的实际药物监测研究
Thomas Lin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag039, https://doi.org/10.1093/jac/dkag039
27
Nationwide patterns of HIV drug resistance and high viral load in Sub-Saharan African countries
撒哈拉以南非洲国家全国范围内的HIV耐药及高病毒载量模式
Abubaker Ibrahim Elbur and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf497, https://doi.org/10.1093/jac/dkaf497
28
Risk factors for suboptimal target attainment of commonly used ß-lactam antibiotics in older adults: a prospective cohort study
老年人常用β-内酰胺类抗生素未达最佳治疗目标的风险因素：一项前瞻性队列研究
Arnaud De Clercq and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag048, https://doi.org/10.1093/jac/dkag048
29
Physiologically based pharmacokinetic modelling to optimize dosing regimen of biapenem in renal impairment and elderly populations
基于生理的药代动力学模型优化肾功能不全及老年人群比阿培南给药方案
Wenyan Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf499, https://doi.org/10.1093/jac/dkaf499
30
Early targeted therapy guided by rapid phenotypic antimicrobial susceptibility testing in critically ill patients with Gram-negative bacterial bloodstream infections: a retrospective cohort study
快速表型抗菌药物敏感性试验指导下的早期目标性治疗对革兰氏阴性菌血流感染危重患者的效果：一项回顾性队列研究
Salvatore Rotundo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag056, https://doi.org/10.1093/jac/dkag056
31
Impact of COVID-19-related healthcare changes on antibiotic resistance in clinical Escherichia coli isolates: interrupted time series analyses in Scotland, UK
与新冠肺炎相关的医疗变化对英国苏格兰地区临床大肠杆菌分离株抗生素耐药性的影响：中断时间序列分析
Laura Ciaccio and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag049, https://doi.org/10.1093/jac/dkag049
32
Multicentre evaluation of teicoplanin prescribing and monitoring in the UK and Ireland: the TUcK–SHOP study
英国和爱尔兰替考拉宁处方与监测的多中心评估：TUcK–SHOP研究
Stephen Hughes and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag038, https://doi.org/10.1093/jac/dkag038
33
Diabetes and risk of significant fibrosis in adults with HIV and metabolic dysfunction-associated steatotic liver disease: a prospective cohort study
糖尿病与HIV合并代谢功能障碍相关脂肪性肝病成人患者发生显著肝纤维化的风险：一项前瞻性队列研究
Win Min Han and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag053, https://doi.org/10.1093/jac/dkag053
34
A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025
基于美国食品药品监督管理局不良事件报告系统（FAERS）数据库2013 - 2025年数据的碳青霉烯类相关药物警戒分析
Connor Frey and Parham Elmi
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag060, https://doi.org/10.1093/jac/dkag060
35
Effects of extracorporeal membrane oxygenation on the pharmacokinetics and tissue penetration rates of vancomycin and linezolid: data from Landrace pigs
体外膜肺氧合对万古霉素和利奈唑胺药代动力学及组织穿透率的影响：来自长白猪的数据
Huifang Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag063, https://doi.org/10.1093/jac/dkag063
36
Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes
在既往存在耐药突变的人类免疫缺陷病毒（HIV）感染者中换用比克替拉韦/恩曲他滨/丙酚替诺福韦治疗。来自意大利ARCA队列的数据：BIC-BARRIER研究。比克替拉韦/恩曲他滨/丙酚替诺福韦（B/F/TAF）换药方案：耐药突变与治疗结果
Laura Pezzati and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag035, https://doi.org/10.1093/jac/dkag035
37
A two-stage diagnostic model for discriminating and assessing risk of meropenem heteroresistance in Pseudomonas aeruginosa
用于鉴别和评估铜绿假单胞菌对美罗培南异质性耐药风险的二阶段诊断模型
Yali Fan and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag061, https://doi.org/10.1093/jac/dkag061
38
Microdialysis assessment of gentamicin for second-line antimicrobial prophylaxis in abdominal surgery
微透析评估庆大霉素在腹部手术中作为二线抗菌预防药物的效果
Quentin Saint-Genis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag071, https://doi.org/10.1093/jac/dkag071
39
Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers
伏立康唑药代动力学及肝毒性的遗传和临床预测因素：聚焦于CYP2C19正常代谢型和中间代谢型
Hui Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag065, https://doi.org/10.1093/jac/dkag065
40
Stakeholder perspectives on the offer and acceptance of self-administration of outpatient parenteral antimicrobial therapy: a qualitative study
利益相关者对提供和接受门诊患者自行注射抗菌药物治疗的看法：一项定性研究
Hester H Stoorvogel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag068, https://doi.org/10.1093/jac/dkag068
41
Is current guidance for cloxacillin prophylaxis dosages in hip and knee arthroplasty adequate? Evidence from a prospective Swedish cohort
当前髋关节和膝关节置换术中氯唑西林预防性用药剂量指南是否充分？来自一项前瞻性瑞典队列研究的证据
Katja Wallander and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag067, https://doi.org/10.1093/jac/dkag067
42
Effect of pretreatment HIV drug resistance on mortality, attrition and viral suppression in patients initiating antiretroviral therapy and genetic transmission network: an observational cohort study in Southwest China
治疗前HIV药物耐药性对开始接受抗逆转录病毒治疗患者的死亡率、失访率和病毒抑制率的影响以及遗传传播网络：中国西南地区一项观察性队列研究
Litai Qin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag073, https://doi.org/10.1093/jac/dkag073
RESEARCH LETTER（研究快讯）
43
Varicella and varicella zoster virus meningoencephalitis in a diffuse large B-cell lymphoma patient after chimeric antigen receptor-T-cell therapy
嵌合抗原受体T细胞疗法后，弥漫性大B细胞淋巴瘤患者发生水痘及水痘-带状疱疹病毒脑膜脑炎
Yan Feng and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag041, https://doi.org/10.1093/jac/dkag041
44
The ‘double hit’ on dalbavancin pharmacokinetics: hypertriglyceridaemia and augmented renal clearance in a child with glycogen storage disease type Ib
糖原累积病Ib型患儿中，高甘油三酯血症和肾清除率增加对达巴万星药代动力学的“双重打击”
Bianca Monti and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag028, https://doi.org/10.1093/jac/dkag028
45
Tn7860, a novel chromosomal pseudo-compound transposon carrying the OptrA gene in Enterococcus faecalis
Tn7860，粪肠球菌中携带OptrA基因的一种新型染色体假复合转座子
Francesca Romana Massacci and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag046, https://doi.org/10.1093/jac/dkag046
46
HBV reactivation after switching to cabotegravir plus rilpivirine therapy among people living with HIV: do not forget the reservoir
HIV感染者换用卡博特韦（cabotegravir）联合利匹韦林（rilpivirine）治疗后乙肝病毒再激活：切勿忽视病毒储存库
Rémi Rouget and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag050, https://doi.org/10.1093/jac/dkag050
47
An inoperable mediastinal infection involving vascular graft treated with weekly oritavancin as chronic suppressive therapy. A case report with pharmacokinetic data
一例涉及血管移植物的无法手术的纵隔感染，采用每周一次的奥利万星作为慢性抑制疗法。附药代动力学数据的病例报告
Pierangelo Chinello and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag013, https://doi.org/10.1093/jac/dkag013
48
Evaluation of the Carbapenemase Detection Kit (Colloidal Gold; Macro & Micro Test): a new immunochromatographic assay for rapid detection of carbapenemases in Enterobacterales
碳青霉烯酶检测试剂盒（胶体金法；宏基因与微基因检测法）评估：一种用于快速检测肠杆菌目细菌中碳青霉烯酶的新型免疫层析法
Hippolyte De Swardt and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag066, https://doi.org/10.1093/jac/dkag066
49
Cefalexin use in UK acute pyelonephritis practice: unaddressed challenges in dosing, breakpoints and clinical evidence
头孢氨苄在英国急性肾盂肾炎治疗中的应用：给药、断点和临床证据方面尚未解决的挑战
Stephen Hughes and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag051, https://doi.org/10.1093/jac/dkag051
LETTERS TO THE EDITOR（致编辑的信）
50
Comment on: Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy
评论：意大利米兰多西环素暴露后预防（DoxyPEP）使用者中用于治疗细菌性性传播感染的抗菌药物使用情况
Chris Kenyon
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag025, https://doi.org/10.1093/jac/dkag025
51
Possible increased risk of Epstein–Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients: right-to-reply
来特莫韦暴露的造血细胞移植受者发生EB病毒（EBV）感染和移植后淋巴增殖性疾病（PTLD）的风险可能增加：答复权
Jose F Camargo and Anthony D Anderson
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag043, https://doi.org/10.1093/jac/dkag043
52
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy—right-to-reply
意大利米兰市使用多西环素暴露后预防（DoxyPEP）人群中，用于治疗细菌性性传播感染的抗菌药物使用情况——答复权声明
Angelo Roberto Raccagni and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag026, https://doi.org/10.1093/jac/dkag026
53
Comment on: Artificial intelligence for improving decision-making in bacterial infection management
述评：人工智能在细菌感染管理决策中的优化作用
Daniele Roberto Giacobbe
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag078, https://doi.org/10.1093/jac/dkag078
CORRECTION（更正）
54
Correction to: Bayesian estimation of the prevalence of antimicrobial resistance: a mathematical modelling study
更正：抗菌药物耐药性流行率的贝叶斯估计：一项数学建模研究
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf494, https://doi.org/10.1093/jac/dkaf494
55
Correction to: National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing
更正：哥伦比亚具有全国代表性的治疗前HIV耐药性调查：使用下一代测序技术分析抗逆转录病毒耐药相关突变
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag057, https://doi.org/10.1093/jac/dkag057
Journal of Antimicrobial Chemotherapy Volume 81, Issue 4抗菌化疗杂志81卷 4期
https://academic.oup.com/jac/issue
50TH ANNIVERSARY COLLECTION（50周年纪念合集）
GARROD LECTURE（加罗德讲座）
1
Garrod lecture: achieving the UNGA AMR mortality reduction goals
加罗德讲座：实现联合国大会抗菌药物耐药性死亡率降低目标
Ramanan Laxminarayan
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag082, https://doi.org/10.1093/jac/dkag082
REVIEW（综述）
2
25 years of improvement in mortality in invasive aspergillosis in haematology patients: will it be sustained or is it under threat?
侵袭性曲霉病血液病患者25年死亡率改善情况：这种改善能否持续，还是正受到威胁？
Johan A Maertens and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag077, https://doi.org/10.1093/jac/dkag077
3
A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 2: from molecule to confirmed hit
针对锥虫病的从高质量潜在客户和药物开发候选者出发的战略发现路线图。第二部分：从分子到确证活性分子
Sarah Hendrickx and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag110, https://doi.org/10.1093/jac/dkag110
VIRTUAL ROUNDTABLE（虚拟圆桌会议）
4
Diagnosis and risk factors for invasive mould disease—a round table discussion on directing antifungal therapy according to the available evidence
侵袭性霉菌病的诊断与危险因素——根据现有证据指导抗真菌治疗的圆桌讨论
Ana Alastruey-Izqueirdo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag062, https://doi.org/10.1093/jac/dkag062
EDITORIALS, MESSAGES FROM THE OUTGOING AND INCOMING EDITORS-IN-CHIEF（社论、离任与就任主编寄语）
5
Message from the incoming Editor-in-Chief of JAC
《抗菌化疗杂志》就任主编寄语
Monica A Slavin
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf479, https://doi.org/10.1093/jac/dkaf479
6
Message from the outgoing Editor-in-Chief
离任主编寄语
J Peter Donnelly
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf480, https://doi.org/10.1093/jac/dkaf480
REVIEW（综述）
7
Experimental biofilm models for pharmacokinetic and pharmacodynamic investigations: bridging in vitro, ex vivo and in vivo systems
用于药代动力学和药效学研究的实验性生物膜模型：连接体外、离体和体内系统
Stephanie Supparitsch and Markus Zeitlinger
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag091, https://doi.org/10.1093/jac/dkag091
8
Antimicrobial therapy for infected necrotizing pancreatitis: microbiology, antimicrobial resistance and pharmacokinetics
感染性坏死性胰腺炎的抗菌治疗：微生物学、抗菌药物耐药性及药代动力学
Hannah S Pauw and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag092, https://doi.org/10.1093/jac/dkag092
9
Continuous linezolid infusion: the new way to dose, the old risks to fear
持续输注利奈唑胺：新的给药方式，仍需警惕旧有风险
Daniel Muñoz-Pichuante and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag100, https://doi.org/10.1093/jac/dkag100
10
Alignment of national standard treatment guidelines with WHO AWaRe recommendations for adult primary care infectious diseases: implications for antimicrobial stewardship
将国家标准治疗指南与世卫组织（WHO）针对成人初级保健传染病的“慎用、监测、备用”（AWaRe）推荐意见相统一：对抗菌药物管理的影响
Huda Arooj and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag099, https://doi.org/10.1093/jac/dkag099
SYSTEMATIC REVIEW（系统综述）
11
Healthcare providers’ experiences in caring for MDRO carriers with a focus on the moral dimensions of care: a systematic review
医疗服务提供者护理多重耐药菌（MDRO）携带者的经历——聚焦护理中的道德维度：一项系统综述
Carlijn Damsté and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag059, https://doi.org/10.1093/jac/dkag059
12
Extrapolation of oritavancin PK/PD targets to inform therapeutic drug monitoring: a systematic review
奥利他万星药代动力学/药效学目标的外推用以指导治疗药物监测：一项系统综述
Giammarco Baiardi and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag117, https://doi.org/10.1093/jac/dkag117
ORIGINAL RESEARCH（论著）
13
Beyond plasma: defining the translation value of epithelial lining fluid exposure profiles for the treatment of pneumonia
超越血浆：明确上皮衬里液暴露谱对肺炎治疗的转化价值
Yakun Fu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf458, https://doi.org/10.1093/jac/dkaf458
14
Impact of loading dose β-lactam therapy on outcomes of KPC-producing Klebsiella pneumoniae bloodstream infections in non-ICU patients: a real world study
负荷剂量β-内酰胺类药物治疗非重症监护病房患者产KPC肺炎克雷伯菌血流感染的疗效影响：一项现实研究
Luisa Frallonardo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag087, https://doi.org/10.1093/jac/dkag087
15
Rezafungin exhibits anti-biofilm properties against fungal biofilms in vitro
雷扎芬净在体外对真菌生物膜表现出抗生物膜特性
Hafsa Abduljalil and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag058, https://doi.org/10.1093/jac/dkag058
16
Vancomycin resistance predicts increased mortality in patients with Enterococcus faecium bloodstream infections: a six-year experience at a large tertiary care Italian hospital
万古霉素耐药性可预测屎肠球菌血流感染患者死亡率增加：意大利一家大型三级医院六年来的经验
Lucia Graziani and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag069, https://doi.org/10.1093/jac/dkag069
17
Fluoroquinolones and the risk of panic attacks: a systematic review and disproportionality analysis using individual case safety reports from the FDA Adverse Event Reporting System (FAERS) database
氟喹诺酮类药物与惊恐发作风险：基于美国食品药品监督管理局不良事件报告系统（FAERS）数据库中个体病例安全报告的系统综述和比例失衡分析
Keeirah Hiertika Raguram and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag083, https://doi.org/10.1093/jac/dkag083
18
Cefuroxime concentrations in facial artery musculomucosal flap, buccal submucosa, subcutaneous tissue, and plasma following bolus or continuous infusion in patients undergoing oral cancer resection: a randomized clinical microdialysis study
在接受口腔癌切除术的患者中，采用随机临床微透析研究，探究头孢呋辛在面动脉肌黏膜瓣、颊黏膜下层、皮下组织和血浆中的浓度（团注或持续输注后）
Johanne Ravn Hansen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag085, https://doi.org/10.1093/jac/dkag085
19
Infection point of care tests bridge the experience gap of antibiotic STOP decisions: clinicians versus students
感染即时检测可弥补抗生素停药决策方面的经验差距：临床医生与学生对比
Archit Singhal and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf486, https://doi.org/10.1093/jac/dkaf486
20
Functional analysis of a novel macrolide–lincosamide resistance gene erm(57) in Cutibacterium avidum
痤疮丙酸杆菌中一种新型大环内酯 - 林可酰胺类耐药基因erm(57)的功能分析
Juri Koizumi and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag029, https://doi.org/10.1093/jac/dkag029
21
HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial
莱索托和坦桑尼亚病毒血症儿童及青少年中的HIV耐药性：GIVE MOVE试验的嵌套分析
Christof Manuel Schönenberger and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag070, https://doi.org/10.1093/jac/dkag070
22
Identification and assessment of paediatric cefepime-induced neurotoxicity in a retrospective cohort of paediatric intensive care patients
在儿科重症监护患者回顾性队列中识别和评估儿科头孢吡肟诱导的神经毒性
Kathryn Pavia and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag075, https://doi.org/10.1093/jac/dkag075
23
Prioritization of adverse events related to integrase inhibitors and NNRTIs: a disproportionality analysis using data from the FAERS database
整合酶抑制剂和非核苷类逆转录酶抑制剂相关不良事件的优先级排序：基于FAERS数据库数据的比例失衡分析
Gao-yang Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag074, https://doi.org/10.1093/jac/dkag074
24
Clinical and immunovirological status in children, adolescents and young adults with early-life-acquired HIV: a Spanish multi-cohort analysis since 2020
自2020年以来西班牙多队列分析中，儿童、青少年及青年时期感染HIV者的临床及免疫病毒学状态
Laura Tarancon-Diez and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag079, https://doi.org/10.1093/jac/dkag079
25
Population pharmacokinetics of meropenem in critically ill adult patients receiving extracorporeal membrane oxygenation—an ASAP ECMO study
接受体外膜肺氧合治疗的危重成年患者美罗培南的群体药代动力学——一项ASAP ECMO研究
Mohd H Abdul–Aziz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag090, https://doi.org/10.1093/jac/dkag090
26
Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: a refined analysis through next-generation sequencing
2022年至2024年意大利流行HIV-1亚型间传播耐药性的评估：通过下一代测序技术进行的精细分析
Daniele Armenia and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag084, https://doi.org/10.1093/jac/dkag084
27
Characterization of efflux pump channel of florfenicol for resistance-enhancing variant RE-CmeABC in Campylobacter
耐药增强型变异体RE-CmeABC中氟苯尼考外排泵通道在弯曲菌中的特性研究
Hong Yao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag047, https://doi.org/10.1093/jac/dkag047
28
Genomic characterization of colistin heteroresistance in Acinetobacter baumannii: Evidence for lpxD deletion and collateral sensitivity
鲍曼不动杆菌中黏菌素异质性耐药的基因组特征：lpxD缺失及附带敏感性的证据
Banu Sancak and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag076, https://doi.org/10.1093/jac/dkag076
29
Sustaining stewardship: longitudinal evaluation of an integrated antimicrobial programme in the ICU
持续管理：重症监护室（ICU）综合抗菌药物管理项目的纵向评估
Ashmitha Thomas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag086, https://doi.org/10.1093/jac/dkag086
30
Global dissemination of optrA-mediated linezolid resistance in enterococci
利奈唑胺耐药性基因optrA介导的肠球菌在全球的传播
Jia Qi Beh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag089, https://doi.org/10.1093/jac/dkag089
31
Predicting oral cephalosporin susceptibility in Escherichia coli blood isolates using parenteral cephalosporin susceptibility testing
利用肠外头孢菌素敏感性试验预测大肠杆菌血培养分离株对口服头孢菌素的敏感性
Tho H Pham and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag093, https://doi.org/10.1093/jac/dkag093
32
The pharmacodynamics of polymyxin B in Acinetobacter baumannii in murine thigh and lung infection models
在小鼠大腿和肺部感染模型中多粘菌素B对鲍曼不动杆菌的药效动力学研究
Sanne van den Berg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag097, https://doi.org/10.1093/jac/dkag097
33
Genomic insights into the tmexCD-toprJ: plasmid-mediated evolution, dissemination and diversity in bacterial populations
关于tmexCD-toprJ的基因组见解：质粒介导的细菌群体进化、传播与多样性
Lilan Wan and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag107, https://doi.org/10.1093/jac/dkag107
34
Baseline resistance mutations and virological response to dolutegravir in treatment-naïve patients: a multicentre NGS study
初治患者基线耐药突变与多替拉韦病毒学应答：一项多中心下一代测序（NGS）研究
Alexy Inciarte and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag080, https://doi.org/10.1093/jac/dkag080
35
Novel integrase mutations linked to genotypic DTG resistance in African non-B HIV-1 strains: the DTG RESIST study
非洲非B型HIV-1毒株中与多替拉韦（DTG）基因型耐药相关的新型整合酶突变：DTG耐药研究
Nuri Han and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag088, https://doi.org/10.1093/jac/dkag088
36
Pharmacological evaluation of an ex vivo cervicovaginal HIV prevention model
体外宫颈阴道HIV预防模型的药理学评估
Lindsey B Collins and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag103, https://doi.org/10.1093/jac/dkag103
37
The magnitude of the pharmacodynamic index for NOSO-502: pathogen clearance, emergence of resistance and human dose predictions
NOSO-502药效学指数的幅度：病原体清除、耐药性出现和人体剂量预测
Sanne van den Berg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag106, https://doi.org/10.1093/jac/dkag106
38
Temocillin: a therapeutic alternative in bone and joint infections due to third generation cephalosporin-resistant Enterobacterales?
替莫西林：治疗第三代头孢菌素耐药肠杆菌目引起的骨关节感染的一种替代疗法？
Louise Piquart and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag105, https://doi.org/10.1093/jac/dkag105
39
Metallo-β-lactamase–producing Enterobacterales: cyanide-containing efflux pump inhibitors as potential dual-activity inhibitors
产金属β-内酰胺酶的肠杆菌科细菌：含氰化物的外排泵抑制剂作为潜在的双活性抑制剂
Otávio Hallal Ferreira Raro and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag122, https://doi.org/10.1093/jac/dkag122
40
Outer membrane vesicles transmit blaNDM-5 and package metallo-β-lactamases to promote antibiotic resistance in Escherichia coli
外膜囊泡传递blaNDM-5并包装金属β-内酰胺酶以促进大肠杆菌的抗生素耐药性
Ting-Yin Lu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag123, https://doi.org/10.1093/jac/dkag123
41
Characterization of a ST412-K57 colistin-resistant hypervirulent Klebsiella pneumoniae strain of chicken origin
一株鸡源ST412-K57多粘菌素耐药高毒力肺炎克雷伯菌的特征分析
Qiu Xu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag114, https://doi.org/10.1093/jac/dkag114
42
Olorofim in combination with azole antifungals: results from the Phase 2 salvage therapy study
奥罗芬明与唑类抗真菌药联合使用：2期挽救治疗研究结果
Johan Maertens and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag118, https://doi.org/10.1093/jac/dkag118
RESEARCH LETTER（研究快讯）
43
Infant HIV transmission despite maternal viral suppression: a case of post-weaning seroconversion
母体病毒得到抑制，婴儿仍发生HIV传播：一例断奶后血清转阳病例
Shadia Nakalema and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag072, https://doi.org/10.1093/jac/dkag072
44
Urinary antigen–negative Legionella pneumonia in critically ill patients: value of systematic molecular testing for optimal antimicrobial therapy
危重患者中尿抗原阴性军团菌肺炎：系统分子检测在优化抗菌治疗中的价值
Livia Foglia Manzillo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag101, https://doi.org/10.1093/jac/dkag101
45
Contribution of SHV-1 overexpression to carbapenem resistance in a Klebsiella pneumoniae clinical isolate
SHV-1过表达对某株肺炎克雷伯菌临床分离株碳青霉烯类抗生素耐药性的影响
Céline Plainvert and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag108, https://doi.org/10.1093/jac/dkag108
LETTER TO THE EDITOR（致编辑的信）
46
Comment on: Possible increased risk of Epstein–Barr virus (EBV) infection and posttransplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients
评论：接受莱特莫韦治疗的造血细胞移植受者中，EB病毒（EBV）感染和移植后淋巴增殖性疾病（PTLD）的风险可能增加
Jan Styczynski
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag042, https://doi.org/10.1093/jac/dkag042
47
Comment on: Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis users in Milan, Italy
评论：意大利米兰地区使用多西环素暴露后预防措施人群中针对细菌性性传播感染的抗菌药物使用情况
Luca Bortolani and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag023, https://doi.org/10.1093/jac/dkag023
48
Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes—right to reply
使用聚丙烯腈膜进行连续肾脏替代治疗的患者中卡泊芬净药物治疗监测的回顾性分析——答复权
Antoine Hérault and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag095, https://doi.org/10.1093/jac/dkag095
49
Comment on: Temocillin versus other intravenous beta-lactams for urinary tract infections caused by third-generation cephalosporin-resistant Enterobacterales: a multicentre retrospective matched-cohort study
评论：替莫西林与其他静脉注射β-内酰胺类抗生素治疗第三代头孢菌素耐药肠杆菌目引起的尿路感染：一项多中心回顾性匹配队列研究
Shanshan Ru and Yingzhe Zhang
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag096, https://doi.org/10.1093/jac/dkag096
50
Comment on: Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?
评论：长效糖肽类抗生素：对于最需要它们的患者，获取的障碍是什么，如何克服？
Marco Bongiovanni
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag102, https://doi.org/10.1093/jac/dkag102
51
Comment on ‘Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes’
评论：“对使用聚丙烯腈膜进行连续肾脏替代治疗的患者中卡泊芬净的药理学治疗监测的回顾性分析”
Julien Massol and Frédéric Baud
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag094, https://doi.org/10.1093/jac/dkag094
52
Comment on: ‘Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp’
对“除塞拉蒂亚属（Serratia spp）外肠杆菌目所致心内膜炎的流行病学和治疗”的评论
Gianpiero Tebano and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag098, https://doi.org/10.1093/jac/dkag098
53
‘Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018–2021-right-to-reply’
“比较肺炎球菌疫苗的血清型覆盖率——PCV21（V116，一种新型21价结合肺炎球菌疫苗）与加拿大成人患者中导致侵袭性肺炎球菌疾病的其8种独特肺炎链球菌血清型（15A、15C、16F、23A、23B、24F、31和35B）的流行病学：SAVE研究，2018 - 2021年——回应”
John J Schellenberg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag126, https://doi.org/10.1093/jac/dkag126
54
Comment on: Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatus
评论：奥罗芬明与伏立康唑对烟曲霉的体外拮抗作用
Corinne Pinder and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag119, https://doi.org/10.1093/jac/dkag119
55
Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp.: right-to-reply
除塞氏杆菌属外肠杆菌科细菌所致心内膜炎的流行病学和治疗：回应
Sunish Shah and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag121, https://doi.org/10.1093/jac/dkag121
2026-04-03
International Journal of Antimicrobial Agents Volume 67, Issue 1
国际抗微生物制剂杂志 67卷 1期
https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/1
International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会新闻与信息页）
1
International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page
国际抗菌化疗学会（ISAC）新闻与信息页
Article 107688
Antimicrobial Pharmacometrics（抗菌药物药代动力学）
2
Model-informed precision pyrazinamide dosing: The establishment of a population pharmacokinetic model repository for clinical decision support
基于模型的精准吡嗪酰胺剂量调整：建立用于临床决策支持的人群药代动力学模型库
Huan Zhang, Lu Han, Xiao-Qin Liu, Juan Wang, ... Zheng Jiao
Article 107658
Global Landscape of Phage Therapy（噬菌体治疗的全球概况）
3
Nanomedicine for phage therapy: Encapsulation strategies for enhanced antimicrobial efficacy
噬菌体治疗的纳米医学：增强抗菌功效的封装策略
Alexis Dorta-Gorrín, Verónica Salgueiriño, Lorena García-Hevia
Article 107660
4
Antibiotic-mediated prophage activation: Mechanisms, consequences, and therapeutic implications
抗生素介导的原噬菌体激活：机制、后果及治疗意义
Damir Gavric, Petar Knezevic
Article 107655
5
Phage therapy for KPC-producing Klebsiella pneumoniae decolonization in high-risk patients: The KIDNAP Study Protocol – A prospective feasibility and proof of concept study in the Brazilian context
噬菌体治疗高风险患者中产KPC肺炎克雷伯菌的定植清除：KIDNAP研究方案——巴西背景下的一项前瞻性可行性及概念验证研究
Iris Najjar, Larissa Simão Gandolpho, Jôiciglecia Pereira dos Santos, Camila de Paula Siqueira, ... Ana C. Gales
Article 107673
AI strategies to combat AMR（人工智能对抗抗菌药物耐药性的策略）
6
Development and validation of machine learning models to predict vancomycin- and teicoplanin-associated acute kidney injury: A retrospective, multicenter study
开发和验证机器学习模型用以预测万古霉素和替考拉宁相关的急性肾损伤：一项回顾性、多中心研究
Pin-Yi Lo, Fan-Ying Chan, Yi-En Ku, San-Yuan Wang, Hsiang-Yin Chen
Article 107651
Reviews（综述）
7
A systematic review and meta-analysis of the global epidemiology of carbapenem-resistant Escherichia coli
碳青霉烯耐药大肠埃希菌全球流行病学的系统综述和荟萃分析
Mikaela M. Walker, Jason A. Roberts, Yixuan Li, Fekade B. Sime
Article 107668
8
Molecular mechanisms of resistance and tolerance of Staphylococcus aureus to daptomycin
金黄色葡萄球菌对达托霉素耐药和耐受的分子机制
Candice Lim, Geoffrey W. Coombs, Shakeel Mowlaboccus
Article 107678
Full Length Articles（长篇论著）
9
Antimicrobial peptide CATH-1 combats Streptococcus suis by targeting serine/threonine kinase
抗菌肽CATH-1通过靶向丝氨酸/苏氨酸激酶对抗猪链球菌
Yi Lu, Xiaoying Yu, Yandi Pan, Hang Yin, ... Rendong Fang
Article 107656
10
The antiarrhythmic drugs dronedarone and amiodarone exhibit potent in vitro and in vivo activity against Clostridioides difficile
抗心律失常药物决奈达隆和胺碘酮对艰难梭菌表现出强效的体内外活性
Ahmed A. Abouelkhair, Nader S. Abutaleb, Mohamed N. Seleem
Article 107649
11
Comparison of ceftazidime-avibactam with other appropriate antimicrobial therapy for the treatment of OXA-48- or KPC-producing Enterobacterales infections in Türkiye: A multi-centre retrospective matched-cohort study
头孢他啶-阿维巴坦与土耳其其他适当抗菌疗法治疗产OXA-48或KPC的肠杆菌目感染的比较：一项多中心回顾性匹配队列研究
Abdullah Tarık Aslan, Elif Seren Tanriverdi, Sibel Yıldız Kaya, Gozde Dalgan, ... Murat Akova
Article 107650
12
An easy-to-use predictive score for identifying patients at risk of suboptimal linezolid exposure and candidates for therapeutic drug monitoring
一种易于使用的预测评分，用于识别存在利奈唑胺暴露不足风险及需进行治疗药物监测的患者
Daniel Fresán, Luisa Sorlí, Jaume Barceló-Vidal, Ana Rodrigo-Moreno, ... Sonia Luque
Article 107661
13
Urinary exosome-derived microRNAs as biomarkers of tenofovir disoproxil fumarate (TDF)-induced renal toxicity in people with HIV-1
尿液外泌体衍生的微小RNA作为HIV-1感染者使用富马酸替诺福韦二吡呋酯（TDF）引起肾毒性的生物标志物
José L. Casado, Pilar Vizcarra, Francisco J. Hernández-Walias, José Manuel del Rey, ... Alejandro Vallejo
Article 107654
14
Global genomic epidemiology of carbapenemase-producing Klebsiella pneumoniae, 1996–2023
1996-2023年产碳青霉烯酶肺炎克雷伯菌的全球基因组流行病学
Yuxia Shi, Dongxiao Ru, Minge Wang, Shengliang Cao, ... Jianbiao Lu
Article 107657
15
Two Tail Protein-Derived Capsule Depolymerases From Phage vB_KpnS_GH-K1 are Effective Against Pneumonia Caused by K2 Serotype Klebsiella pneumoniae
来自噬菌体vB_KpnS_GH-K1的两种尾蛋白衍生的荚膜多糖解聚酶对K2血清型肺炎克雷伯菌引起的肺炎有效
Guiyang Ge, Hongbei Ge, Jianhui Xu, Bing Yue, ... Rui Du
Article 107662
16
Discrepancy between WGS-based genotypic and phenotypic drug susceptibility testing of first and second-line drugs for Mycobacterium tuberculosis: Limited impact of unknown resistance mechanisms
结核分枝杆菌一线和二线药物基于全基因组测序的基因型与表型药物敏感性测试之间的差异：未知耐药机制的影响有限
Ruimin Hong, Peng Xu, Wenjie Lai, Chi Wu, ... Qian Gao
Article 107666
17
Consumption and expenditure on fidaxomicin and oral vancomycin for Clostridioides difficile infection: A 12-year longitudinal study of 43 countries and regions
43个国家和地区12年艰难梭菌感染使用菲达霉素和口服万古霉素的消费和支出情况纵向研究
Yin Zhang, Xue Li, Angel Y.S. Wong, Vincent K.C. Yan, ... Wai K. Leung
Article 107664
18
Genome-wide insight into the evolution and global transmission of tigecycline resistant tet(X4)-carrying Klebsiella species across reservoirs
全基因组视角下携带耐替加环素tet(X4)的克雷伯菌属在各储存库中的进化与全球传播
Yuye Wu, Yawen Yu, Xueqian He, Weifang Mao, ... Zhi Ruan
Article 107665
19
Combined disk-based tests for phenotypic identification of KPC variants in Enterobacterales
基于联合药敏试验的肠杆菌目中KPC变异体的表型鉴定
Feng Yang, Li Ding, Siquan Shen, Chengkang Tang, ... Fupin Hu
Article 107663
20
Impact of antimicrobial resistance measures and the emergence of COVID-19 on antimicrobial use throughout the Japanese population: A retrospective cohort study using a national claims database
抗菌药物耐药性措施的实施及新冠疫情的出现对日本全民抗菌药物使用的影响：一项使用国家索赔数据库的回顾性队列研究
Ryuji Koizumi, Shinya Tsuzuki, Yusuke Asai, Kensuke Aoyagi, Norio Ohmagari
Article 107667
21
Ceftazidime-avibactam resistance among clinical isolates of Citrobacter freundii, Morganella morganii, Providencia spp. and Serratia marcescens across five continents: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2016–2023
2016-2023年抗菌药物测试领导与监测（ATLAS）项目数据：五大洲弗氏柠檬酸杆菌、摩氏摩根菌、普罗维登斯菌属和产气肠杆菌临床分离株对头孢他啶-阿维巴坦的耐药性
Hao-En Jan, Jiun-Ling Wang, Nan-Yao Lee, Shun-Chung Hsueh, ... Po-Ren Hsueh
Article 107669
22
Impact of DNA-stored mutations on virological response in virologically suppressed PWH in the switch to modern regimens
DNA储存突变对病毒抑制的HIV感染者转换至现今治疗方案时病毒学反应的影响
Francesca Lombardi, Elio Gentilini Cacciola, Federica Carli, Francesco Saladini, ... Maria Mercedes Santoro
Article 107670
23
NucS Thr74Ile confers mutator phenotype in a globally disseminated clinical Mycobacterium abscessus subsp. abscessus clone
NucS Thr74Ile在全球传播的临床脓肿分枝杆菌脓肿亚种克隆中赋予突变表型
Juan Li, Junsheng Fan, Zhili Tan, Anqi Li, ... Haiqing Chu
Article 107677
24
Adverse effects of posaconazole on adrenal steroid biosynthesis: An integrative approach using FAERS-based pharmacovigilance and systematic review with meta-analysis of randomised controlled trials
泊沙康唑对肾上腺类固醇生物合成的不良影响：基于FAERS的药物警戒和随机对照试验系统综述与荟萃分析的综合方法
Yuki Nakano, Kazumasa Kotake, Yuki Asai, Masayuki Murata, ... Hirotsugu Hasuwa
Article 107676
25
SU3327: A multi-target compound targeting bacterial menaquinone and DNA
SU3327：一种靶向细菌甲基萘醌和DNA的多靶点化合物
Shuge Wang, Ke Zhao, Ziqi Chen, Chengtao Sun, ... Dejun Liu
Article 107679
26
blaKPC-2 amplification and a novel mrcA mutation drive Cefiderocol heteroresistance in ST11 CRKP
blaKPC-2扩增和一种新型mrcA突变驱动ST11碳青霉烯耐药肺炎克雷伯菌对头孢地尔的异质性耐药
Yuxuan Liu, Hanxu Hong, QianBin Dai, Linping Fan, ... Yang Liu
Article 107682
27
P1-like phage-plasmids drive blaCTX-M-27 transmission through lysogenic conversion and transposition
P1样噬菌体质粒通过溶原性转换和转座驱动blaCTX-M-27传播
Zengfeng Zhang, Chunlei Shi
Article 107686
28
Streptomyces taklimakanensis sp. nov. TRM43335 produces 3-indole carbaldehyde a promising inhibitor of carbapenem-resistant Acinetobacter baumannii: In vitro and in vivo evaluation
塔克拉玛干沙漠放线菌新种Streptomyces taklimakanensis sp. nov. TRM43335产生3-吲哚甲醛——一种有前景的碳青霉烯耐药鲍曼不动杆菌抑制剂：体内外评估
Yanchun Qin, Wen ting Zhou, Ling Wang, Shengqiang Yang, ... Hong Zeng
Article 107685
Short Communications（短篇通讯）
29
Fluconazole exposure during mechanical circulatory support (MCS) device insertion
机械循环支持（MCS）装置植入期间的氟康唑暴露
Kelly A. Cairns, Kate Morton, Trisha N. Peel, Iain J. Abbott, ... Michael J. Dooley
Article 107647
30
Evaluation of sulbactam-durlobactam disk diffusion and broth microdilution methods for Acinetobacter baumannii
评估磺苄西林-杜洛巴坦对鲍曼不动杆菌的纸片扩散法和肉汤微量稀释法
Xiaolan Hong, Xinying Wang, Xin Xiang, Siquan Shen, ... Yan Guo
Article 107659
Letters to the Editor（读者来信）
31
Comment on “Comparison of ceftazidime-avibactam with other appropriate antimicrobial therapy for the treatment of OXA-48- or KPC-producing Enterobacterales infections in Turkiye: A multi-centre retrospective matched-cohort study”
对“土耳其头孢他啶-阿维巴坦与其他适当抗菌疗法治疗产OXA-48或KPC的肠杆菌目感染的比较：一项多中心回顾性匹配队列研究”的评论
S. Dhanya Dedeepya, Vaishali Goel, Nivedita Nikhil Desai
Article 107671
32
Emergence of TMexCD-TOprJ-producing Vibrio furnissii in retail shellfish
零售贝类中出现产TMexCD-TOprJ的弗尼斯弧菌
Haotian Deng, Zhongpeng Cai, Kexin Li, Ludan Xiao, ... Shaowen Li
Article 107680
International Journal of Antimicrobial Agents Volume 67, Issue 2
国际抗微生物制剂杂志 67卷 2期
https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/2
1
Title Page & Editorial Board
标题页与编委会
Article 107727
International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会（ISAC）新闻与信息页）
2
International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page
国际抗菌化疗学会（ISAC）新闻与信息页
Article 107719
Systematic Reviews and Meta-analyses（系统综述与荟萃分析）
3
Ceftazidime/avibactam and ceftolozane/tazobactam for severe paediatric infections: A systematic review, meta-analysis, and evidence map
头孢他啶/阿维巴坦与头孢洛扎/他唑巴坦治疗儿童重症感染：一项系统评价、荟萃分析及证据图谱研究
Paula Pimenta-de-Souza, Alice Ramos-Silva, Valcieny Sandes, Patrícia Portella, ... Elisangela Costa Lima
Article 107710
Full Length Articles（长篇论著）
4
Downregulation of an NfsA-like nitroreductase causes metronidazole resistance in Gardnerella vaginalis
NfsA样硝基还原酶下调可导致阴道加德纳菌对甲硝唑耐药
Ana Paunkov, Anna-Lena Mayr, Vera Oberbauer, Timo Schwebs, ... David Leitsch
Article 107681
5
Machine–learning and gene–synergy networks reveal interpretable drivers of antibiotic resistance in Staphylococcus aureus
机器学习与基因协同网络揭示金黄色葡萄球菌抗生素耐药性的可解释驱动因素
Jie Xu, Yuan Li, Ying Wang, Fang Liu, ... Haiyan Yang
Article 107690
6
Enhanced molecular surveillance for gonococcal resistance during doxycycline post-exposure prophylaxis implementation
在实施多西环素暴露后预防措施期间加强对淋球菌耐药的分子监测
Ziyuan Zhao, Leshan Xiu, Junping Peng
Article 107689
7
Fosfomycin-based combinations against carbapenemase-producing Klebsiella pneumoniae bloodstream infections: Correlating in vitro synergy with clinical outcomes
以磷霉素为基础的联合用药治疗产碳青霉烯酶肺炎克雷伯菌血流感染：体外协同作用与临床预后的相关性
Melike Törüyenler Coşkunpınar, Güle Çınar, Duygu Öcal, İsmail Balık
Article 107687
8
EnvZ mutation–driven downregulation of catecholate siderophore receptors and concurrent TonB complex repression confer cefiderocol resistance in a KPC-producing ST11-KL64 hypervirulent Klebsiella pneumoniae
EnvZ突变驱动儿茶酚酸铁载体受体下调表达，同时抑制TonB复合体，使产KPC酶的ST11-KL64型高毒力肺炎克雷伯菌对头孢地尔产生耐药性
Danni Pu, Xianxia Zhuo, Rongrong Song, Chunhui Wang, ... Bin Cao
Article 107693
9
Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis
治疗肾盂肾炎和复杂性尿路感染的抗生素类别比较：一项系统综述和荟萃分析
Digbijay Kunwar, Itay Zahavi, Judit Olchowski, Hagar Dallasheh, Mical Paul
Article 107696
10
Enhancing meropenem therapy in critical care: A retrospective study of PK/PD target attainment and therapeutic drug monitoring
强化重症监护病房中美罗培南的治疗：一项关于药代动力学/药效学目标达成情况及治疗药物监测的回顾性研究
Jingli Liao, Chao Li, Jingxian Liu, Wei Wu, ... Lixia Li
Article 107697
11
Zinc deficiency reverses biofilm azole resistance in Candida albicans
锌缺乏可逆转白色念珠菌生物膜对唑类药物的耐药性
Yingzhe Wang, Shigan Ye, Yuan Deng, Yingting Huang, Xiaoliang Zhu
Article 107695
12
Development of ceftazidime–avibactam resistance driven by conversion of blaKPC-2 to blaKPC-78 during treatment of ST463 carbapenem-resistant Pseudomonas aeruginosa infection
治疗ST463型碳青霉烯类耐药铜绿假单胞菌感染过程中，因blaKPC-2基因突变为blaKPC-78基因而引发的头孢他啶-阿维巴坦耐药性的产生
Haotian Xu, Tingjuan Zhang, Xueying Cui, Jingyi Guo, ... Xi Li
Article 107703
13
ATP-binding cassette transporters mediate and regulate metronidazole resistance in Clostridioides difficile
ATP结合盒转运蛋白介导并调控艰难梭菌对甲硝唑的耐药性
Teng Xu, Ying Zhou, Qingqing Xu, Li Wang, ... Haihui Huang
Article 107709
14
Regorafenib, a multitargeted kinase inhibitor, inhibits enterovirus 71 infection by suppressing the MAPK pathway
瑞戈非尼（Regorafenib）作为一种多靶点激酶抑制剂，可通过抑制丝裂原活化蛋白激酶（MAPK）通路来抑制肠道病毒71型感染
Xinyu Zhang, Yuanyuan Cao, Yu Liu, Shengqun Deng, ... Qi Tang
Article 107711
Short Communications（短篇通讯）
15
Effect of ibuprofen on the pharmacokinetics of intravenous flucloxacillin in healthy adults
布洛芬对健康成年人静脉注射氟氯西林药代动力学的影响
Alison Boast, Amy Legg, James McCarthy, Jason A Roberts, ... Amanda Gwee
Article 107684
16
Formation of a novel multiresistance plasmid co-carrying tigecycline, carbapenem, and other resistance genes by recombination during conjugative transfer in Klebsiella pneumoniae
肺炎克雷伯菌在接合转移过程中通过重组形成一种共携带替加环素、碳青霉烯类及其他耐药基因的新型多重耐药质粒
Runhao Yu, Zhong Chen, Stefan Schwarz, Hong Yao, ... Xiang-Dang Du
Article 107683
17
Vancomycin clearance compared to creatinine clearance by timed urine collection in the intensive care unit
重症监护室中通过定时尿液收集法比较万古霉素清除率与肌酐清除率
Andrew Chantha Hean, Rinoj Mathew, Frank Chu, Linda Awdishu
Article 107704
18
Risk of infective endocarditis in oncohaematological patients undergoing active treatment with Enterococcus faecalis bloodstream infection: A retrospective multicentre study
接受积极治疗的血液肿瘤患者合并屎肠球菌（Enterococcus faecalis）血流感染时发生感染性心内膜炎的风险：一项回顾性多中心研究
Miguel Ángel Consuegra Pérez, Sara Grillo, Alexander Rombauts, María Alba Rivera Martínez, ... Laura Escolà-Vergé
Article 107706
Letters to the Editor（致编辑的信）
19
In reply to the letter to editor regarding “Comparison of ceftazidime-avibactam with other appropriate antimicrobial therapy for the treatment of OXA-48- or KPC-producing Enterobacterales infections in Turkiye: A multi-centre retrospective matched-cohort study”
针对就《土耳其头孢他啶-阿维巴坦与其他适宜抗菌疗法治疗产OXA-48或KPC肠杆菌科感染的对比：一项多中心回顾性匹配队列研究》一文致编辑的信的回复
Abdullah T. Aslan, Patrick N.A. Harris, David L. Paterson
Article 107691
20
Aztreonam–avibactam pharmacokinetics during extracorporeal membrane oxygenation support: First insights from a case report
体外膜肺氧合支持期间氨曲南-阿维巴坦的药代动力学特征：首例病例报告的初步见解
Alba Pau-Parra, Sònia Luque, Laura Doménech, María Martínez-Pla, ... Jordi Riera
Article 107692
21
Comments on ‘Acute kidney injury associated with colistin sulphate vs. polymyxin B sulphate therapy: A real-world, retrospective cohort study’
对“硫酸黏菌素与硫酸多黏菌素B治疗相关急性肾损伤：一项真实世界回顾性队列研究”的评论
Genzhu Wang
Article 107702
22
Superintegron of Vibrio paracholerae as a reservoir of antibiotic resistance genes
副霍乱弧菌（或拟霍乱弧菌）超级整合子作为抗生素耐药基因的储存库
Sergio Mascarenhas Morgado, Erica Lourenço da Fonseca, Ana Carolina Paulo Vicente
Article 107708
23
Clinical outcomes of metronidazole dosing strategies in obese patients with Bacteroides bloodstream infections
肥胖患者脆弱拟杆菌（Bacteroides）血流感染时甲硝唑不同给药策略的临床疗效
Sunish Shah, Rachel V. Marini, Dayna McManus, Ryan K. Shields, ... Tyler Tate
Article 107701
Corrigendum（勘误表）
24
Corrigendum to “Impact of antimicrobial resistance measures and the emergence of COVID-19 on antimicrobial use throughout the Japanese population: A retrospective cohort study using a national claims database” [International Journal of Antimicrobial Agents Volume 67(2026)107667]
对《抗菌药物耐药性评估及新冠疫情的爆发对日本全民抗菌药物使用情况的影响：一项基于国家医保理赔数据库的回顾性队列研究》[《国际抗微生物制剂杂志》第67卷（2026年）第107667篇]的勘误说明
Ryuji Koizumi, Shinya Tsuzuki, Yusuke Asai, Kensuke Aoyagi, Norio Ohmagari
Article 107694
International Journal of Antimicrobial Agents Volume 67, Issue 3
国际抗微生物制剂杂志 67卷3期
https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/3
1
Title Page & Editorial Board
目录与编委会
Article 107753
International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会（ISAC）新闻与资讯页面）
2
International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page
国际抗菌化疗学会（ISAC）新闻与资讯页面
Article 107746
Hot Topic（热点）
3
Artificial intelligence and machine learning in antimicrobial discovery, resistance prediction, and precision therapy
人工智能与机器学习在抗菌药物发现、耐药性预测及精准治疗中的应用
Reema Singh, Yu-Wei Lin, Jinxin Zhao, Jian Li
Article 107715
Reviews（综述）
4
Pharmacokinetics and pharmacodynamics of bacteriophage therapy: A scoping review
噬菌体治疗的药代动力学和药效学：一项范围综述
Andrew T Nguyen, Nicita Mehta, KaiLan Mackey, Thomas Cummiskey, ... Jason Young
Article 107705
5
Effect of probiotic strain, duration, and dose on preventing ICU-acquired infection: A scoping review
益生菌菌株、疗程及剂量对预防重症监护病房（ICU）获得性感染的影响：一项范围综述
Aqdar Mufareh Al-Aklabi, Sara Muteb Alotaishan, Yasmin Youssuf Al-Gindan, Rabie Yousif Khattab
Article 107714
Full Length Articles（完整论著）
6
Pharmacokinetics of ampicillin, sulbactam and combined ampicillin/sulbactam in subcutis, muscle and plasma: A microdialysis trial in healthy volunteers
氨苄西林、舒巴坦及氨苄西林/舒巴坦联合用药在皮下、肌肉和血浆中的药代动力学：一项健康志愿者微透析试验
Anselm Jorda, Lena Pracher, Marlene Prager, Felix Bergmann, ... Valentin al Jalali
Article 107716
7
Beneficial effects of a compound probiotic in Helicobacter pylori-infected patients aged over 40 years: An open-label randomised clinical trial
复合益生菌对40岁以上幽门螺杆菌感染患者的有益作用：一项开放标签随机临床试验
Chenghai Yang, Jie Cheng, Meng Zhang, Bingyun Lu, ... Ye Chen
Article 107712
8
Skin pharmacokinetics and pharmacodynamics in patients with post-kala-azar dermal leishmaniasis
内脏利什曼病（黑热病）后皮肤利什曼原虫病患者的皮肤药代动力学与药效学
Wan-Yu Chu, Om Prakash Singh, Shyam Sundar, Krishna Pandey, ... Thomas P. C Dorlo
Article 107713
9
Amodiaquine hydrochloride facilitates mycobacterial clearance via triggering autophagy in macrophages
盐酸阿莫地喹通过触发巨噬细胞自噬促进分枝杆菌清除
Hongxuan Yan, Jinfeng Yuan, Shujuan Duan, Fuzhen Zhang, ... Mengqiu Gao
Article 107720
Short Communications（短篇通讯）
10
Risk factors for bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii in ICU patients with any site colonisation: a prospective observational study
重症监护病房（ICU）患者任何部位定植碳青霉烯耐药鲍曼不动杆菌造成血流感染的危险因素：一项前瞻性观察研究
Giusy Tiseo, Valentina Galfo, Aurelio Lepore, Manuela Pogliaghi, ... Marco Falcone
Article 107717
11
Resistance to sulbactam/durlobactam in carbapenem-resistant Acinetobacter baumannii in treatment-naive setting: in vitro data and genomic insights from Italian bloodstream isolates
初次用药背景下耐碳青霉烯鲍曼不动杆菌对舒巴坦/杜洛巴坦的耐药性：来自意大利血流感染分离株的体外数据及基因组见解
Gabriele Bianco, Gherard Batisti Biffignandi, Matteo Boattini, Sara Comini, ... Paolo Gaibani
Article 107718
12
Real-world daptomycin use with a focus on muscle toxicity: A multicentric retrospective study
聚焦肌肉毒性的达托霉素实际使用情况：一项多中心回顾性研究
C. Airaud, E. Demay, V. Dias Meireles, D. Luque Paz, ... A. Bacle
Article 107721
International Journal of Antimicrobial Agents Volume 67, Issue 4
国际抗微生物制剂杂志 67卷4期
https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/4
1
Title Page & Editorial Board
目录与编者按
Article 107775
International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会（ISAC）新闻与信息）
2
International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page
国际抗菌化疗学会（ISAC）新闻与信息
Article 107765
Hot Topic（热点）
3
Phage therapy in China: Arming the One Health approach
中国噬菌体疗法：助力“同一健康”策略实施
Na Li, Qimao Yang, Bijie Hu, Tongyu Zhu, Nannan Wu
Article 107731
Global Landscape of Phage Therapy（噬菌体疗法的全球概况）
4
CRISPR/Cas9-engineered Salmonella phage displaying antimicrobial peptide LL37 for enhanced antibacterial activity
利用CRISPR/Cas9技术改造的沙门氏菌噬菌体，展示出抗菌肽LL37，用以增强抗菌活性
Su Jin Jo, Se Chang Park, Sang Guen Kim
Article 107734
5
Phage resistance bidirectionally altered antibiotic susceptibility in Klebsiella pneumoniae via galE mutation
噬菌体抗性通过galE基因突变双向改变肺炎克雷伯菌的抗生素敏感性
Braira Wahid, Sue C. Nang, Jinxin Zhao, Zhi Ying Kho, ... Jian Li
Article 107738
Reviews（综述）
6
Resistance of uropathogens to gepotidacin: A systematic review of in vitro antimicrobial susceptibility studies
尿路病原体对吉培西林（gepotidacin，一种新型抗菌药）的耐药性：体外抗菌敏感性研究的系统综述
Matthew E. Falagas, Laura T. Romanos, Eleni D. Katritsi, Iva D. Tzvetanova
Article 107723
Full Length Articles（完整论著）
7
Identification of KPC-271, a novel KPC variant conferring ceftazidime-avibactam resistance while restoring carbapenem susceptibility in ST15-KL19 Klebsiella pneumoniae
新型KPC变体KPC-271的鉴定：该变体使ST15-KL19型肺炎克雷伯菌对头孢他啶-阿维巴坦产生耐药性，同时恢复其对碳青霉烯类的敏感性
Hongjian Ou, Siquan Shen, Chengkang Tang, Weiwei Yang, ... Fupin Hu
Article 107725
8
Rapid detection of NDM-producing carbapenem-resistant Escherichia coli using MALDI-TOF MS combined with machine learning techniques
基质辅助激光解吸电离飞行时间质谱（MALDI-TOF MS）结合机器学习技术快速检测产新德里金属β-内酰胺酶（NDM）的碳青霉烯类耐药大肠杆菌
Rongrong Dong, Yifei Wang, Lei Song, Jiayin Wang, ... Jiancheng Xu
Article 107726
9
Global distribution and genomic architectures of plasmid-mediated quinolone resistance genes in Shigella from 1998 to 2025
1998年至2025年志贺氏菌中质粒介导的喹诺酮类耐药基因的全球分布及基因组结构特征
Juan Geng, Cheng Cheng, Xu Liu, Jinzhao Long, ... Guangcai Duan
Article 107737
Short Communications（快报）
10
Global epidemiological trend of Klebsiella pneumoniae ST23: Emergence of KL57 lineage carrying dual carbapenemases
肺炎克雷伯菌ST23型全球流行病学趋势：携带双碳青霉烯酶的KL57谱系的出现
Shuangshuang Li, Guoli Li, Xueqian He, Yawen Yu, ... Zhi Ruan
Article 107722
11
Antibiotic susceptibility of Gram-negative bacteria in cerebrospinal fluid compared with Mueller-Hinton broth and artificial cerebrospinal fluid
脑脊液中革兰氏阴性菌对Mueller-Hinton肉汤和人工脑脊液的抗生素敏感性比较
Katrin Biesner, Marija Djukic, Utz Reichard, Roland Nau, Jana Seele
Article 107730
Letters to the Editor（致编辑的信）
12
Global, regional, and national burden of multidrug-resistant organisms, 1990–2021
1990 - 2021年全球、区域及国家层面多重耐药菌的疾病负担
Lian Liu, Hong Luo
Article 107724
13
Beyond categorical agreement: Antibiotic-specific time to result in rapid susceptibility testing from Gram-negative positive blood cultures
超越分类一致性：针对革兰氏阴性菌血培养阳性的快速药敏试验中不同抗生素的结果检出时间
Tiziana D’Inzeo, Damiano Squitieri, Cataldo Maria Mannavola, Matteo Zelinotti, ... Brunella Posteraro
Article 107735
14
Comment on “Phage therapy for KPC-producing Klebsiella pneumoniae de colonisation in high-risk patients: The KIDNAP Study Protocol”
对“针对高危患者中产KPC肺炎克雷伯菌定植的噬菌体疗法：KIDNAP研究方案”的评论
Yinjia Lou, Yiqing Han
Article 107733
微生物疗法临床1期
100 项与 泊沙康唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 毛霉菌感染 | 日本 | 2020-01-23 | |
| 曲霉菌病 | 中国 | 2013-06-03 | |
| 念珠菌病 | 美国 | 2006-09-15 | |
| 侵袭性真菌感染 | 澳大利亚 | 2006-03-15 | |
| 接合菌病 | 澳大利亚 | 2006-03-15 | |
| 着色霉菌病 | 欧盟 | 2005-10-25 | |
| 着色霉菌病 | 欧盟 | 2005-10-25 | |
| 着色霉菌病 | 冰岛 | 2005-10-25 | |
| 着色霉菌病 | 冰岛 | 2005-10-25 | |
| 着色霉菌病 | 列支敦士登 | 2005-10-25 | |
| 着色霉菌病 | 列支敦士登 | 2005-10-25 | |
| 着色霉菌病 | 挪威 | 2005-10-25 | |
| 着色霉菌病 | 挪威 | 2005-10-25 | |
| 球孢子菌病 | 欧盟 | 2005-10-25 | |
| 球孢子菌病 | 欧盟 | 2005-10-25 | |
| 球孢子菌病 | 冰岛 | 2005-10-25 | |
| 球孢子菌病 | 冰岛 | 2005-10-25 | |
| 球孢子菌病 | 列支敦士登 | 2005-10-25 | |
| 球孢子菌病 | 列支敦士登 | 2005-10-25 | |
| 球孢子菌病 | 挪威 | 2005-10-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 深部真菌病 | 临床3期 | - | 2014-07-29 | |
| 肺曲霉菌病 | 临床3期 | - | 2014-07-29 | |
| 侵袭性肺曲霉菌病 | 临床3期 | - | 2013-09-25 | |
| 白细胞减少 | 临床3期 | - | 2008-11-01 | |
| 急性髓性白血病 | 临床3期 | - | 2002-07-01 | |
| 骨髓增生异常综合征 | 临床3期 | - | 2002-07-01 | |
| 中性粒细胞减少 | 临床3期 | - | 2002-07-01 | |
| 口腔念珠菌病 | 临床3期 | 美国 | 1998-08-01 | |
| 口腔念珠菌病 | 临床3期 | 巴巴多斯 | 1998-08-01 | |
| HIV感染 | 临床3期 | 美国 | 1998-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床4期 | 10 | Matching Placebo Tablet (Placebo) | 齋壓製窪鑰齋鬱衊壓蓋 = 積醖願鹽積壓簾積鏇憲 網獵構願衊鑰構築遞觸 (艱簾獵願蓋築願觸鬱糧, 鑰顧醖餘鏇憲鏇艱膚積 ~ 糧鬱廠膚鬱鬱遞蓋顧選) 更多 | - | 2026-02-24 | ||
(Posaconazole) | 齋壓製窪鑰齋鬱衊壓蓋 = 製顧網選餘齋淵築願願 網獵構願衊鑰構築遞觸 (艱簾獵願蓋築願觸鬱糧, 窪鹹膚憲夢衊築範齋鑰 ~ 繭積選繭膚憲蓋蓋顧鏇) 更多 | ||||||
N/A | 8,068 | 壓獵餘夢顧觸構獵艱糧(鑰觸壓艱鑰鑰獵築選獵) = 範繭艱遞網鑰衊選顧築 繭鏇醖獵觸鬱醖淵鑰範 (鑰鑰顧糧鬱範鏇鏇膚遞 ) 更多 | 积极 | 2025-12-06 | |||
壓獵餘夢顧觸構獵艱糧(鑰觸壓艱鑰鑰獵築選獵) = 獵壓繭齋顧窪獵構鹽鏇 繭鏇醖獵觸鬱醖淵鑰範 (鑰鑰顧糧鬱範鏇鏇膚遞 ) 更多 | |||||||
N/A | 急性髓性白血病 CYP3A enzymes | 31 | 鏇夢積齋淵窪襯壓醖願(鹽膚餘醖醖築糧憲遞遞) = 壓夢膚鹽壓繭製廠積蓋 廠襯範壓積齋遞壓餘鏇 (窪遞簾醖鏇膚網願簾糧 ) 更多 | 积极 | 2025-05-30 | ||
鏇夢積齋淵窪襯壓醖願(鹽膚餘醖醖築糧憲遞遞) = 衊網鑰構艱齋蓋衊網蓋 廠襯範壓積齋遞壓餘鏇 (窪遞簾醖鏇膚網願簾糧 ) 更多 | |||||||
临床4期 | 88 | standard of care (SOC)+Posaconazole (SOC + 'Posaconazole 18 MG/ML') | 窪願網夢餘糧廠憲鹽遞 = 衊襯願製夢糧範廠遞鏇 艱築鏇構鏇範膚範繭醖 (艱憲鑰鹽醖窪遞襯糧鹹, 廠鹽積憲衊構鑰鬱鏇築 ~ 膚壓構鬱積構憲鬱壓觸) 更多 | - | 2025-04-08 | ||
standard of care (SOC) (Standard of Care) | 窪願網夢餘糧廠憲鹽遞 = 齋憲齋餘積簾範鬱壓夢 艱築鏇構鏇範膚範繭醖 (艱憲鑰鹽醖窪遞襯糧鹹, 願築觸憲選鹹顧築製構 ~ 夢廠選築糧襯製網願窪) 更多 | ||||||
临床2期 | 10 | 願構醖觸製醖淵構鹽窪 = 憲製淵艱獵蓋繭顧醖憲 鹽網鑰窪醖願範積壓獵 (壓顧齋醖鏇製繭積鬱遞, 憲網襯艱鏇觸簾網獵顧 ~ 顧獵範獵製簾製醖衊製) 更多 | - | 2025-01-22 | |||
临床2期 | 31 | (Age Cohort 1 (2 -< 12 Years Old)) | 鹹餘淵範簾夢遞蓋範觸 = 構醖壓範簾顧積構廠遞 蓋製窪鬱顧遞選鏇壓齋 (艱餘餘繭壓窪衊簾夢鏇, 艱鹹衊鹽廠蓋鏇繭鑰製 ~ 鏇顧鬱襯淵簾簾鹹憲築) 更多 | - | 2025-01-14 | ||
(Age Cohort 2 (12 -< 18 Years Old)) | 鹹餘淵範簾夢遞蓋範觸 = 夢選齋築積遞膚積齋夢 蓋製窪鬱顧遞選鏇壓齋 (艱餘餘繭壓窪衊簾夢鏇, 壓積願獵繭築壓廠鏇鏇 ~ 遞壓選鏇餘獵製淵繭鑰) 更多 | ||||||
N/A | - | 窪廠淵顧鏇齋壓齋願繭(簾範蓋積淵糧齋衊願齋) = 艱鹹窪餘膚繭夢餘齋膚 憲繭願選築窪齋構淵衊 (觸範廠糧齋襯積餘淵鹹 ) | 积极 | 2025-01-01 | |||
No antifungal prophylaxis | 窪廠淵顧鏇齋壓齋願繭(簾範蓋積淵糧齋衊願齋) = 壓選憲壓遞艱艱糧選鏇 憲繭願選築窪齋構淵衊 (觸範廠糧齋襯積餘淵鹹 ) | ||||||
临床2期 | 20 | 鏇願夢獵壓築醖鹹選餘 = 艱壓窪製積願蓋鏇壓網 顧壓簾遞餘齋艱廠窪鹹 (鹽壓簾餘鏇鬱觸製鹽襯, 糧膚獵膚壓餘範膚鏇積 ~ 願窪糧願壓鑰壓廠製積) 更多 | - | 2024-12-20 | |||
N/A | - | 鬱繭淵鑰壓鬱膚製製窪(衊衊網繭糧壓窪壓觸襯) = There were no significant differences in survival outcomes, in months, including PFS (5.7 vs 4.2, p=0.53) 鹽膚淵餘鏇獵鏇網獵獵 (範蓋壓鹹糧鹽鑰醖鹽淵 ) 更多 | - | 2024-12-07 | |||
临床2期 | 20 | Posaconazole 300mg twice daily | 鑰艱憲觸簾網蓋範廠夢(觸網積築網鬱蓋繭夢鑰) = 窪憲醖積範遞壓餘餘鏇 廠範觸蓋遞憲築鑰襯築 (餘積艱鑰繭膚襯衊艱糧 ) 更多 | 积极 | 2024-05-14 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用